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ABSTRACT 
 
Facioscapulohumeral muscular dystrophy (FSHD) region gene 1 (FRG1) is 
critical for development of the vertebrate musculature and vasculature, however its 
precise molecular function is unknown.  Because of its location 125 kb proximal to the 
FSHD1A lesion, a deletion in a subtelomeric macrosatellite DNA repeat array, it has 
been considered a candidate for mediating FSHD pathophysiology.  This study 
investigates FRG1’s function to provide insight into FRG1’s role in vertebrate muscle 
development.  First, we focus on the subcellular localization of FRG1 and identified 
FRG1 as a dynamic nuclear, cytoplamic, and sarcomeric protein.  During myoblast 
differentiation, FRG1’s subcellular distribution changed dramatically with FRG1 
eventually associating with the matured Z-discs.  The Z-disc localization is confirmed in 
mouse myofibers, suggesting FRG1 may have a muscle-specific function involved in 
sarcomere maintenance or signaling.  The nuclear fraction of the endogenous FRG1 is 
localized in nucleoli, Cajal bodies, and actively transcribed chromatin associated with 
nascent RNA transcripts, supporting a function in RNA biogenesis.  Furthermore, we 
show that FRG1 interacts specifically with RNA in vitro, associates with mRNA in vivo, 
and directly interacts with the TAP mRNA export receptor.  FRG1 also exists in a 
cytoplasmic pool that is dependent on an intact actin cytoskeleton for its localization and 
we demonstrate FRG1 itself is an actin binding protein.  These data provide the first 
biochemical activities for human FRG1 and indicate that FRG1 dynamically shuttles 
between the nucleus and cytoplasm and is involved in aspects of RNA biogenesis, 
potentially including mRNA transport and localization. 
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CHAPTER 1 
INTRODUCTION 
 
FSHD PATHOLOGY 
Facioscapulohumeral muscular dystrophy (FSHD) is the most prevalent form of 
muscular dystrophy in adults (incidence of 1:7,500 – 14,000), and overall the third most 
common after Duchenne and myotonic muscular dystrophy (2009; Lunt and Harper, 1991; 
Padberg, 1982).  FSHD is inherited in an autosomal dominant manner with approximately 
10-30% of affected individuals carrying a de novo mutation (Padberg et al., 1995).  FSHD 
is marked by progressive and often asymmetric atrophy in specific muscle groups.  As the 
name implies, FSHD initially affects facial, shoulder, and upper arm muscles, and later 
extends to pelvic girdle and lower extremities (Olsen et al., 2006; Tawil, 2008).  Age of 
onset is highly variable, ranging from early infancy to late fifties, but most patients 
become symptomatic in their second decade (Tawil and Van Der Maarel, 2006).  There is 
also a wide variety in progression rate and clinical severity from asymptomatic individuals 
to patients who eventually require a wheelchair (approximately 20% of affected 
individuals) (Pandya et al., 2008).  In addition, several extramuscular manifestations in 
FSHD have been described including high frequency hearing loss and retinal 
telangiectasias in 75% and 60% of patients, respectively (Fitzsimons et al., 1987; Padberg 
et al., 1995).  Although these manifestations are typically asymptomatic, FSHD retinal 
vasculopathy in severe cases can lead to retinal detachment and blindness, similar to 
symptoms observed in Coat’s disease (Fitzsimons et al., 1987).  
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FSHD GENETIC DEFECTS 
The genetic lesion of FSHD is located on the subtelemeric region of chromosome 
4q (4q35.2), where 95% of the patients carry a contraction in an array of 3.3 kb 
macrosatellite repeats, termed D4Z4 (van Deutekom et al., 1993; Wijmenga et al., 1992).  
The contraction results in a decrease of repeat number below a threshold of 11, whereas 
normal individuals carry 11-100 repeats (Figure 1.1).  A lower repeat number often 
correlates to more severe symptoms, although loss of all repeats units does not result in 
FSHD (Lunt et al., 1995; Lunt et al., 1995).  However, there is high degree of interfamilial 
and intra-familial variability of disease expression with the same size deletion indicating 
the deletion size is not the only determinant of severity.  Interestingly, monosomy of the 
4q35 D4Z4 region does not cause FSHD (Tupler et al., 1996), and homozogosity for the 
FSHD lesion does not result in a more severe phenotype (Tonini et al., 2004) suggesting 
the lesion results in a gain of function localized to 4q35. 
A repeat array that is highly homologous to D4Z4 array was found on 
chromosome 10q26 (Bakker et al., 1995; Deidda et al., 1995).  The D4Z4 array on 10q26 
is over 98% homologous to the 4q35 array (Figure 1.1), and the homology extends both 
proximally (42 kb) and distally to include the telomere (Cacurri et al., 1998; van Geel et 
al., 2002).  This region is also polymorphic with repeat number varying between 1-100 
units (van Overveld et al., 2000).  Sub-telomeric exchange of the repeat array between 
10q26 and 4q35 is observed in 20% of individuals (van Deutekom et al., 1996; van 
Overveld et al., 2000).  However, contraction of D4Z4 repeats array on 10q26 does not 
cause FSHD suggesting additional cis regions specific to chromosome 4q mediate the 
disease pathophysiology (Bakker et al., 1995; Lemmers et al., 1998). 
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To further complicate the genetic defect in FSHD, there are two allelic variants of 
chromosome 4q, 4qA and 4qB (Figure 1.1) (van Geel et al., 2002).  The two variants are 
distinguished by the presence of a 260-bp sequence (pLAM) followed by a 6.2 kb β -
satellite repeat in 4qA (Lemmers et al., 2002).  Despite the equal frequency of 4qA/B in 
the population (42% and 58%, respectively), FSHD is exclusively associated with the 4qA 
type (Lemmers et al., 2002; Lemmers et al., 2004).  Using a combination of polymorphic 
markers, including a single nucleotide polymorphism (SNP) within the most proximal 
copy of D4Z4 unit, a simple sequence length polymorphism (SSLP) that’s 3.5 kb 
proximal to the repeat array (Figure 1.2), and the A/B variation, subtelomeric region of 
chromosome 4q can be subdivided into at least 9 haplotypes (Lemmers et al., 2007).  
There are three haplotypes within 4qA, of which only 4qA161 is found to be associated 
with FSHD.  This allele is nonpathogenic since 4qA161 haplotype was found in 86% of 
normal individuals with 4qA allele, however, it is FSHD permissive since it is required in 
combination with the D4Z4 deletion for disease progression (Lemmers et al., 2007).  
FSHD EPIGENETICS 
Since the FSHD genetic defect is not a classical mutation within a known protein-
coding gene, it’s been postulated that the contraction results in mis-regulation of 4q35 
genes through an epigenetic mechanism.  To understand the chromatin structure of 4q35 
D4Z4 array, the field has studied this region in respects of DNA methylation, histone 
modifications, and nuclear organization. 
 D4Z4 repeat units have an unusually high GC content (73%) with characteristics 
of CpG islands and containing two repetitive sequences, LSau and hhspm3, which are 
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predominantly found in heterochromatic regions (Hewitt et al., 1994; Lee et al., 1995).  
Generally, DNA methylation on CpG islands correlates to increased chromatin 
condensation and gene silencing.  The D4Z4 region in individuals with FSHD is marked 
by DNA hypomethylation compared to healthy individuals.  Furthermore, individuals with 
phenotypic FSHD (FSHD2) without a contracted D4Z4 (~5% of FSHD patients) also have 
DNA hypomethylation of this D4Z4 region (Tsien et al., 2001; van Overveld et al., 2003).  
These data support that changes in the epigenetic landscape of 4q35 may lead to FSHD 
pathophysiology. 
 The chromatic nature of 4q35 was also characterized by chromatin 
immunoprecipitation assay (ChIP) using an antibody specific for acetylated histone H4, a 
marker for transcriptionally active chromatin.  The H4 acetylation levels of the region 
adjacent to 4q35 D4Z4 arrays were like those found in unexpressed euchromatin rather 
than the levels indicative of constitutive heterochromatin found in normal and FSHD 
lymphoid cells (Jiang et al., 2003).  Fluorescence in situ hybridization (FISH) analysis of 
4q35 using cultured myoblasts from both FSHD patients and healthy individuals showed 
that 4q35 region does not co-localize with heterochromatic markers, nor with histone H4 
lysine 8 (H4K8) acetylation, a marker for highly expressed euchromatin, (Jiang et al., 
2003).  The 4q35 FISH results confirmed that 4q35 region resembles unexpressed 
euchromatin rather than constitutive heterochromatin meaning the region may be more 
susceptible to epigenetic changes affecting localized gene expression. 
 Mammalian chromosomes occupy distinct territories in the nucleus; and many 
nuclear functions, such as transcription, RNA-processing, and replication, take place in 
well-defined nuclear compartments (Francastel et al., 2000; Manuelidis, 1984).  Unlike 
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other chromosome ends studied, the FSHD region near the chromosome 4q telomere is 
closely associated with the nuclear periphery in several cell types (Masny et al., 2004).  
The nuclear envelope and associated lamina are the nuclear domain that play a role in 
gene expression, chromatin organization, and differentiation (Marshall, 2003).  
Interestingly, several neuromuscular disorders result from deficiencies in components of 
the nuclear envelope, such as Emery-Dreifuss muscular dystrophy (EDMD) (Burke and 
Stewart, 2002; Ostlund and Worman, 2003).  This finding suggests that FSHD may arise 
through aberrant interactions of distal 4q chromatin with the nuclear envelope. 
 
FSHD DISEASE MODELS   Several models have emerged to explain how the contraction in D4Z4 array leads 
to FSHD pathogenesis.  These include the loss of silencing of a transcript within each 
D4Z4 called DUX4, loss of silencing of proximal 4q35 genes similar to the position effect 
variegation (PEV), altered nuclear organization model, and chromosome looping model. 
  
D4Z4 gene expression model 
 A putative double homeodomain gene, DUX4, was identified within each D4Z4 
repeat unit.  It was proposed that the partial deletion of the D4Z4 repeat array resulted in 
destabilization of the D4Z4 heterochromatin and the inappropriate upregulation of DUX4 
(Figure 1.3A) (Gabriels et al., 1999; Hewitt et al., 1994).  The functionality of the DUX4 
gene has been questioned due to the lack of introns and polyadenylation signals, and 
absence of transcription in vivo (Alexiadis et al., 2007; Gabriels et al., 1999; Hewitt et al., 
1994; Osborne et al., 2007; Winokur et al., 2003).  However, recent studies showed that 
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the open reading frame (ORF) of DUX4 is conserved in several mammalian species 
suggesting a coding role, and expression of mouse Dux4 genes was detected (Clapp et al., 
2007).  Further, expression of two different DUX4 transcripts in cells transfected with 
D4Z4 elements and in FSHD myoblasts were reported (Kowaljow et al., 2007).  This 
transcript contains two introns and is transcribed from the most distal D4Z4 repeat unit 
(Dixit et al., 2007).  Interestingly, the pLAM sequence immediately distal to the D4Z4 
array, which is found in the 4qA haplotype mentioned above, may provide the 
polyadenylation signal for the transcript.  This distal DUX4 transcript can only be 
observed in FSHD myotubes but not in control myotubes. 
 
Cis-spreading model 
 Another model predicts an indirect role for the D4Z4 contraction in FSHD 
pathogenesis, in which D4Z4 contraction may alter the chromatin structure of the array, 
like D4Z4 hypomethylation, and lead to loss of silencing of candidate gene in cis (Figure 
1.3B).  A D4Z4 binding element (DBE) within the D4Z4 repeat unit was identified, which 
recruits a repressor complex consists of YY1, a transcription factor that can act as 
transcription activator or repressor; HMGB2, an chromatin architectural protein; and 
RNA-binding protein nucleolin, which is involved in transcriptional control of ribosomal 
RNA and in ribogenesis (Gabellini et al., 2002).  This repressor complex was shown to 
bind to D4Z4 in vitro and in vivo, and mediate transcriptional repression of 4q35 genes; 
4q35 genes, FRG2, FRG1, and ANT1, were found transcriptionally upregulated in a 
distance-dependent manner in FSHD muscle samples.  However, further expression 
analysis could not confirm the unregulation of these 4qter genes in FSHD samples (Jiang 
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et al., 2003; Klooster et al., 2009; Masny et al., 2010; Osborne et al., 2007; Winokur et al., 
2003).  Further, the normal 4q35 region is not constitutive heterochromatin as previously 
described, and this model failed to explain why FSHD is only linked to the 4qA 
phenotype while contraction on 4qB is non-pathogenic.   
Altered chromosome looping model   A nuclear matrix attachment site (S/MAR) was identified and located in the 
proximal vicinity of the D4Z4 repeat array, which is important for the organization of 
DNA into loop domains as part of a higher order chromatin structure (Razin et al., 2007).  
This S/MAR site was found to be prominent in normal human myoblasts, however, much 
weaker in muscle cells derived from FSHD patients, suggesting that the D4Z4 repeat array 
and upstream genes reside in two loops in normal human myoblasts but in only one loop 
in FSHD (Figure 1.3C) (Petrov et al., 2006).  Further, a strong transcriptional enhancer 
resides in the 5’ end of the D4Z4 repeat unit was identified, therefore, altering 
chromosome looping in this region may results in the upregulation of neighboring genes 
(Petrov et al., 2008). 
 
Nuclear organization model 
  FSHD region, the subtelomeric region of chromosome 4q, is closely associated 
with the nuclear periphery across several cell types as previously described (Masny et al., 
2004).  Importantly, this localization seems to be dependent on the presence of lamin A/C, 
a major component of the nuclear lamina underlying the nuclear envelope, since this 
peripheral localization of 4qter is lost in cells deficient of lamin A/C (Masny et al., 2004).  
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No disturbed localization was observed for the disease allele in myoblasts derived from 
FSHD patients compared to controls (Masny et al., 2004).  An independent study has also 
demonstrated the intrinsic properties of 4qter are necessary and sufficient to localize this 
subtelomeric domain in the nuclear periphery (Tam et al., 2004).  In this nuclear 
localization model, FSHD may arise through aberrant interactions of distal 4q chromatin 
with transcription factors or chromatin modifiers at the nuclear envelope, leading to 
change of transcriptional regulation of proximal genes (Figure 1.3D). 
 
FSHD CANDIDATE GENES 
Although the exact disease mechanism of FSHD is unclear, FSHD D4Z4 deletion 
likely results in the epigenetic misregulation of one or more 4q35 localized genes (de 
Greef et al., 2008; van der Maarel and Frants, 2005).  There are multiple FSHD candidate 
genes in proximity to the 4q35 D4Z4 array, including FSHD region gene 1 (FRG1), 
FSHD region gene 2 (FRG2), adenine nucleotide translocator 1 (ANT1), DUX4c, and one 
putative gene within the array, DUX4 (Figure 1.4). 
 
FRG2 and ANT1 
FRG2, located 37 kb proximal to the D4Z4 array, has no known function, has 
never been shown to produce a protein in vivo, and is not conserved beyond humans 
(Klooster et al., 2009).  However, FRG2 is transcriptionally upregulated in differentiating 
primary myoblast cultures derived from FSHD patients (Rijkers et al., 2004).  
Interestingly, it was shown that the upregulation of FRG2 mainly originated from 
chromosome 10q26 rather than 4q35.  Like other candidate genes, FRG2 misregulation in 
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FSHD is controversial (Jiang et al., 2003; Osborne et al., 2007; Winokur et al., 2003), and 
expression analysis failed to detect FRG2 transcripts in biopsy samples from FSHD 
patient or normal controls (Klooster et al., 2009).  Transgenic mice over-expressing FRG2 
did not develop a muscular dystrophy phenotype (Gabellini et al., 2006).  Furthermore, 
patients with a deletion that extends into the proximal non-repeated region including 
FRG2 are clinically indistinguishable from FSHD patients indicating FRG2 gain of 
expression is not involved in FSHD (Deak et al., 2007; Lemmers et al., 2003). 
The ANT1 gene encodes a conserved mitochondrial protein that facilitates export 
of ATP over the mitochondrial membrane.  ANT1 levels were shown to be increased in 
both unaffected and affected FSHD muscles compared to controls.  Increased expression 
level of ANT1 may sensitize cells to oxidative stress and apoptosis (Laoudj-Chenivesse et 
al., 2005).  Misregulation of ANT1 in FSHD is also controversial and transgenic mice 
overexpressing ANT1 did not have an FSHD-like phenotype (Gabellini et al., 2006; 
Gabellini et al., 2002; Tupler et al., 1999). 
 
DUX4 and DUX4c   A putative gene was identified within each D4Z4 unit designated DUX4 (double 
homeobox gene 4).  DUX4 expression was detected in FSHD myoblasts but not in normal 
myoblasts; and expression of mouse Dux4 gene was reported (Clapp et al., 2007; 
Kowaljow et al., 2007).  DUX4 protein expression may induce apoptosis and caspase 3/7 
activity, and alters emerin distribution at the nuclear envelope (Kowaljow et al., 2007).  
Another study reported DUX4 could activate transient expression of a luciferase reporter 
gene fused to the Pitx1 promoter as well as the endogenous Pitx1 gene (paired-like 
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homeodomain transcription factor 1) in transfected C2C12 cells (Dixit et al., 2007).  
PITX1 is a member of a paired family of homeoproteins and is involved in specification 
of hind limb identity.  PITX1 was found to be specifically upregulated in patients with 
FSHD compared to controls (Dixit et al., 2007).  However, recent expression analysis 
could not confirm the overexpression of PITX1 (Klooster et al., 2009; Masny et al., 2010).  
Further, both DUX4 and PITX1 appear to be extremely toxic for cells; expression of even 
very low levels of either DUX4 or pitx1 in X. laevis led to massive cellular loss and 
severely abnormal development, and these abnormalities were not muscle specific 
(Wuebbles et al., 2010).  More studies are required in order to determine if DUX4 is 
involved in FSHD pathogenesis. 
An inverted copy of DUX4 was found approximately 40 kb proximal to D4Z4 
array, termed DUX4c (Double homeobox 4 centromeric) (Wright et al., 1993).  DUX4c 
protein expression was detected in primary myoblasts, and a 2-10 fold upregulation was 
observed in FSHD myoblasts and muscle biopsies compared to control (Ansseau et al., 
2009).  DUX4c overexpression was shown to induce MYF5 expression, a myogenic 
regulator, which is known to inhibit myoblast differentiation (Ansseau et al., 2009).  
However, extended proximal deletion of the D4Z4 array including DUX4c was reported in 
some FSHD patients makes DUX4c a less likely candidate gene for FSHD. 
 
FRG1 
FRG1 was one of the earliest candidate genes for FSHD since it was the first gene 
identified in the 4q35 region (van Deutekom et al., 1996).  FRG1 is located 125 kb 
centromeric to D4Z4 array, and is very highly conserved from vertebrates to invertebrates 
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(human FRG1 shares 97%, 81%, and 46% homology with mouse, Xenopus, and C. 
elegans, respectively; see Figure 1.5) suggesting important biological functions that were 
conserved throughout evolution (Grewal et al., 1998).  Like other FSHD candidate genes, 
multiple expression profile studies failed to show consistent results that FRG1 is mis-
regulated in FSHD samples, with expression changes varying from 25-fold increased, 
unchanged, and 5-fold decreased compared with controls (Gabellini et al., 2002; Jiang et 
al., 2003; Klooster et al., 2009; Masny et al., 2010; Osborne et al., 2007; van Deutekom et 
al., 1996).  However, unlike FRG2 and ANT1, altering FRG1 expression levels have led 
to an FSHD-like phenotype in multiple animal models including mouse, Xenopus, and C. 
elegans (Gabellini et al., 2006; Hanel et al., 2009; Liu et al., 2010; Wuebbles et al., 2009).  
Significantly, among the FSHD candidate genes, FRG1 is the only one that has been 
shown to be required for normal development of both the vasculature and the musculature, 
the two affected tissues in FSHD, and its overexpression leads to both muscular and 
vascular FSHD-like phenotypes (Hanel et al., 2009; Wuebbles et al., 2009) as discussed 
below.  Thus, FRG1 is the most viable FSHD candidate gene. 
 
EFFECTS OF ALTERED FRG1 EXPRESSION LEVELS ON DEVELOPMENT   Protein and mRNA expression profile studies have failed to determine 
conclusively if FRG1 is mis-regulated in FSHD.  How, or if, FRG1 misexpression could 
mediate FSHD disease pathogenesis is unknown due to the lack of understanding of 
FRG1’s molecular function.  However, altering expression levels of FRG1 in animal 
models have led to disrupted musculature and vasculature, the two prominent features of 
FSHD. 
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FRG1 is critical for muscle development   Transgenic mice over-expressing FRG1 (with a 25-40 fold increase) in skeletal 
muscle results in an FSHD-like phenotype: smaller muscle fibers, reduction in body 
weight, and muscle atrophy (Gabellini et al., 2006).  Altering expression levels of frg1 in 
developing frogs (Xenopus laevis) revealed frg1 is critical for muscle development.  More 
specifically, decreasing frg1 protein levels by antisense morpholino microinjection 
disrupted myotome organization and inhibited myotome growth; increasing frg1 protein 
levels by mRNA injection led to abnormal epaxial and hypaxial muscle formation (Hanel 
et al., 2009).  In addition, overexpressing FRG-1 in C. elegans specifically from the frg-1 
promoter disrupts the adult ventral muscle structure and organization (Liu et al., 2010).  
All results support that maintaining normal levels of FRG1 is critical for muscle 
development.  
FRG1 is crucial for developing vasculature   In addition to muscular symptoms, 50-75% of FSHD patients also exhibit retinal 
vasculopathy (Fitzsimons et al., 1987).  Characterizing endogenous frg1 expression in X. 
laevis using an antibody specific for frg1 revealed that frg1 is expressed in both the 
developing and adult vasculature.  Decreasing frg1 levels results in decreased 
angiogenesis, while overexpressing FRG1 lead to pro-angiogenic phenotypes of increased 
blood vessel branching and dilation (Wuebbles et al., 2009).  These results showed that 
mis-regulation of FRG1 leads to disrupted vascular phenotype, which is the first link 
between a 4q35 candidate gene and the vasculature phenotype in FSHD pathology.  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FRG1 IN RNA­BIOGENESIS 
Very little is known about the FRG1 protein and no biological activity has been 
described for FRG1.  Domain analysis of FRG1 revealed two nuclear localization signals 
(NLS) residing in the N-terminus, one bipartite NLS domain in the C-terminus, and a 
fascin-like domain, found in actin-bundling and cross-linking proteins in the middle 
(Kureishy et al., 2002; van Koningsbruggen et al., 2004).  Several lines of evidence 
suggest FRG1 is involved in RNA biogenesis.  Epitope-tagged FRG1 overexpressed in 
vertebrate cell culture appears completely nuclear, and localized to the nucleoli, Cajal 
bodies, and nuclear speckles, sites where RNA-biogenesis is taking place (van 
Koningsbruggen et al., 2004).  FRG1 has been found to associate with RNA processing 
components and large-scale proteomic studies revealed that FRG1 is associated with 
human spliceosome complex (Rappsilber et al., 2002; van Koningsbruggen et al., 2007).  
Furthermore, mis-spliced mRNA transcripts were found in transgenic mice 
overexpressing Frg1 (Gabellini et al., 2002).  However, there is no direct evidence of 
FRG1’s specific role in RNA biogenesis, and the subcellular localization of the 
endogenous human FRG1 has not been characterized.  
STUCTURE­FUNCTION ANALYSIS OF FRG1   Whether or not FRG1 is involved in FSHD pathogenesis is not clear due in part to 
the lack of understanding of FRG1’s molecular function. Despite the proposed role of 
FRG1 in RNA-biogenesis, the precise function of FRG1 remains unknown.  Here, we 
want to focus on the function of human FRG1. First, subcellular localization of 
endogenous human FRG1 was investigated in multiple cell types.  To determine if FRG1 
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plays a role in muscle differentiation, the subcellular localization of FRG1 was monitored 
during myogenesis using cultured human skeletal muscle myoblasts.  In addition, the 
nuclear localization of endogenous FRG1 was characterized in order to further investigate 
FRG1’s role in RNA biogenesis.  The potential direct association of FRG1 with RNA was 
investigated in vivo and in vitro using RNA-immunoprecipitation (RNA-IP) and RNA 
binding assay, respectively.  Finally, the fascin domain in FRG1 suggests FRG1 may 
bundle actin or associate with the actin cytoskeleton.  The human FRG1 actin-bundling 
activities were characterized and the localization of endogeneous FRG1 was investigated 
in cells with disrupted actin cytoskeleton.  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Figure 1.2: Subtelomeric region of chromosome 4q can be subdivided into several 
haplotypes.  Simple sequence length polymorphism (SSLP), SNP within the most 
proximal D4Z4 unit, and A/B variation were used as polymorphism markers to distinguish 
the allelic haplotypes within chromosome 4q. 
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Figure 1.3: Disease models proposed for FSHD. Several disease models have been 
proposed to explain how the contraction in D4Z4 leads to FSHD pathogenesis. These 
include the D4Z4 gene expression model (A), Cis-spreading model (B), altered 
chromosome looping model (C), and nuclear organization model (D). 
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Figure 1.4: Multiple candidate genes proposed for FSHD. There are multiple FSHD 
candidate genes in proximity to or within the 4q35 D4Z4 array. The putative ORF within 
D4Z4 is indicated, and D4Z4 binding element (DBE) is represented by the gray circle. 
 
 
 
 
 
Figure 1.5: FRG1 protein is very highly conserved in vertebrate and invertebrate.  
A ClustalW sequence comparison of the predicted amino acid sequences for the human, 
mouse, Xenopus laevis, Drosophila melanogaster, and Caenorhabditis elegans FRG1 
homologs. 
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CHAPTER 2* 
SUBCELLULAR LOCALIZATIONS OF ENDOGENOUS FRG1 
* Some of the data and writing is adapted from 
 
 Meredith L. Hanel, Chia-Yun Jessica Sun, Steven W. Long, Takako I. Jones, Derek Milner, and 
Peter L. Jones. Facioscapulohumeral muscular dystrophy (FSHD) region gene 1 (FRG1) is a dynamic 
nuclear and sarcomeric protein. Submitted for publication.  
INTRODUCTION 
FRG1, located 125kb centromeric to the FSHD1A deletion, was one of the early 
candidate genes for FSHD (van Deutekom et al., 1996).  However, recent expression 
studies have failed to find significant FRG1 misexpression in numerous FSHD patient 
derived muscle cells and biopsies casting doubt on its involvement in mediating FSHD 
pathology (Gabellini et al., 2002; Jiang et al., 2003; Klooster et al., 2009; Masny et al., 
2010; Osborne et al., 2007; van Deutekom et al., 1996).  Complicating the issue is the lack 
of understanding towards FRG1’s cellular function and it’s potential role during normal 
human muscle development.  Initial studies using Xenopus as a model for vertebrate 
development found frg1 was widely expressed early and throughout development, 
showing elevated levels in vascular tissues and developing muscles with preferential 
expression in the capillaries, veins, and arteries located between muscle fibers (Hanel et 
al., 2009; Wuebbles et al., 2009).  Knockdown and overexpression experiments confirmed 
a necessary role for frg1 in development of the musculature and vasculature.  Systemic 
increases in frg1 levels had specific effects on the developing musculature and 
vasculature, impairing myogenesis and muscle precursor cell migration and causing 
spurious angiogenesis leading to a tortuous vasculature (Hanel et al., 2009; Wuebbles et 
al., 2009).  These phenotypes are consistent with the two major pathologies seen in FSHD 
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patients (Gieron et al., 1985; Padberg, 1982).  A similar developmental analysis of the C. 
elegans FRG1 ortholog (FRG-1) showed the conserved expression profile of very early, 
throughout development, and in many different cell-types (Liu et al., 2010).  Again, the 
development, organization, and integrity of the adult body wall musculature were unique 
in their susceptibility to increased FRG-1 levels.  Interestingly, FRG-1 had to be 
overexpressed in the spaciotemporal pattern dictated by the FRG-1 promoter and there 
was no affect on the musculature when FRG-1 was overexpressed specifically in adult 
muscle.  Thus, although FRG1 may function in many tissues, the developing musculature 
and vasculature are uniquely susceptible to systemic changes in FRG1 levels suggesting 
FRG1 has tissue specific functions.  In FSHD, pathogenic changes in FRG1 expression 
may be occurring early in muscle development or also involve non-myogenic cell lineages 
(Hanel et al., 2009; Liu et al., 2010; Wuebbles et al., 2009). 
Little is known about FRG1’s precise function.  Overexpression studies in cell 
culture initially characterized FRG1 as a nuclear and predominantly nucleolar protein (van 
Koningsbruggen et al., 2004; van Koningsbruggen et al., 2007).  In addition, FRG1 has 
been identified as a component of the spliceosome (Rappsilber et al., 2002).  Therefore, 
FRG1’s biological activity likely involves aspects of RNA biogenesis.  Our previous work 
in C. elegans showed that the endogenous FRG-1 is both a nuclear and cytoplasmic 
protein, localizing to the nucleoli and body wall muscle dense bodies, respectively (Liu et 
al., 2010).  Consistent with its localization to muscle attachment sites, FRG-1 was shown 
to exhibit F-actin binding and bundling activity and this activity was conserved with its 
human homolog, FRG1 (Liu et al., 2010).  This is particularly intriguing from a muscular 
dystrophy perspective since the C. elegans dense bodies form the muscle attachments and 
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function analogous to the vertebrate Z-discs and costameres combined [reviewed 
in(Moerman and Williams, 2006)].  Many proteins within or associated with the structures 
involved in the contractile apparatus and the muscle attachment structures are linked to 
other myopathies [reviewed in (McNally and Pytel, 2007; Selcen and Carpen, 2008)].  
While providing potential insight into FRG-1’s function in human muscle development 
and disease, it is not known how these results translate to the human condition and 
potentially FSHD.  Here, we present an analysis of endogenous human FRG1 in muscle 
cells during myogenesis and in mouse myofibers.  We identified three subcellular pools of 
FRG1, nuclear, cytoplasmic, and sarcomeric in muscle and show that FRG1 is dynamic, 
shuttling between the nucleus and cytoplasm.  Interestingly we found FRG1’s subcellular 
distribution during human skeletal muscle myogenesis changes dramatically, finally 
becoming sarcomeric.  Overall, our results show that in vertebrates FRG1 is a dynamic 
nuclear and sarcomere-associated protein suggesting linked roles in the nucleus and at 
muscle attachment sites. 
 
RESULTS 
Endogenous FRG1 has nuclear and cytoplasmic subcellular localizations  
To understand the potential for FRG1 to mediate FSHD pathophysiology we first 
need to understand the normal cellular and developmental function of FRG1 in human 
muscle. We have recently characterized the C. elegans FRG1 homolog as being both a 
nuclear protein and associated with body-wall muscle sarcomeres (Liu et al., 2010).  To 
characterize the endogenous human FRG1 protein in respect to subcellular localization in 
skeletal myoblasts and through myogenesis into myotubes, we generated three 
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independent highly specific anti-FRG1 antibodies, HS1, HS2, and DM1 (Figure 2.1).  
Western blotting of HeLa whole cell extracts showed each affinity-purified antibody 
reacted to the predicted 30kDa FRG1 polypeptide, however, the DM1 antibody also 
recognized a smaller 18kDa polypeptide (Figure 2.2M).  The identity of this smaller 
fragment is not known, however, BLAST searches of the NCBI human non-redundant 
protein database indicated that the peptides used for immunization are each unique in the 
human genome and the 18kDa polypeptide likely represents an alternative form of FRG1.  
The 4q35 localized FRG1 gene, the only locus containing all nine exons, is partially 
duplicated at several other genomic loci and alternatively spliced FRG1 transcripts have 
been previously reported (van Deutekom et al., 1996).  Although all three antibodies 
appear highly specific for FRG1 by western blotting, the primary technique used in this 
study is immunocytochemistry (ICC).  Therefore, to characterize the specificity of the 
antibodies for ICC, a specific siRNA-mediated knockdown approach was used.  HeLa 
cells were transfected three consecutive times with a pool of 4 siRNAs specific to human 
FRG1, subjected to immunostaining with each of the FRG1 antibodies, and compared to 
controls (Figure 2.2A-L).  Each of the FRG1 antibodies showed similar immunostaining 
patterns with varying intensities of both cytoplasmic and nuclear staining.  In all cases the 
FRG1 signal was severely depleted or absent in the siRNA treated cells (Figure2.2, 
compare C, D with A, B; G, H with E, F; and K, L with I, J).  Due to the fact that 
transfection efficiency was less than 100%, some cells were still positive for FRG1 
staining and served as positive controls for the immunostaining procedure.  We conclude 
that all three of our FRG1 antibodies are specific for FRG1 in immunohistochemistry.   
  29 
As opposed to overexpressed epitope-tagged FRG1 that appears exclusively 
nuclear in cell culture (van Koningsbruggen et al., 2004), the endogenous FRG1 in HeLa 
cells clearly appears to be both nuclear and cytoplasmic by immunostaining.  Western 
blotting of HeLa cell extract fractionated into nuclear and cytoplasmic pools confirmed 
the dual subcellular localization of FRG1 (Figure 2.2N).  Although HeLa cells are a 
commonly used human cell line for many studies of protein function because they are fast 
growing and easily transfected, they are HPV17 transformed immortal adenocarcinoma 
cells, quite distant from the muscle cells in which we are interested in studying.  
Therefore, the unexpected cytoplasmic subcellular localization of human FRG1 was 
further addressed in multiple cell types including HeLa cells, normal human skeletal 
myoblasts, murine muscle derived stem cells (MDSC), and murine C2C12 cells (Figure 
2.3).  In HeLa and C2C12 cells, FRG1 was predominantly localized to nuclei, however 
the cells displayed distinct, non-uniform fiber-like cytoplasmic FRG1 immunostaining 
strongly suggesting an association with a subcellular architecture.  In the human 
myoblasts (Figure 2.3Q) and the murine MDSCs (Figure 2.3U) the nuclear FRG1 was 
much less pronounced compared with the cytoplasmic staining which appeared to 
surround the nucleus and was very granular.  We conclude that endogenous FRG1 exists 
in both a nuclear and cytoplasmic pool in all cell types tested, however its cytoplasmic to 
nuclear distribution is cell type dependent. 
 
FRG1 is a nuclear-cytoplasmic shuttling protein   
The endogenous FRG1 is localized in both the nucleus and cytoplasm.  Nuclear 
shuttling assays were performed (Figure 2.4) to determine if these two pools of FRG1 
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were linked.  Murine C2C12 cells, easily identifiable by their DNA-dense nuclear foci, 
were transfected with a plasmid expressing epitope tagged HA-FRG1 and allowed to 
accumulate HA-FRG1 overnight.  Cycloheximide (CHX) was added to the culture media 
to block translation and the cells were fused with non-transfected HeLa cells, readily 
identifiable by their DNA poor nucleoli, in continued presence of CHX, and HA-FRG1 
localization was monitored over time by ICC probing for HA.  Thus, any HA signal in the 
HeLa cells represents FRG1 protein synthesized in the C2C12 cells.  Within two hours of 
starting the fusion FRG1 synthesized in a C2C12 cell (Figure 2.4A-D, white arrow) had 
begun to accumulate in the nuclei and concentrate the in nucleoli of a fused HeLa cell 
(Figure 2.4A-D, blue arrow).  This nuclear import of FRG1 was more evident at three 
hours (Figure 2.4E-H) and at four hours appeared to have reached equilibrium (Figure 
2.4I-L).  As the amount of cytoplasmic HA-FRG1 is almost undetectable, we deduce that 
much of the HeLa nuclear HA-FRG1 came from the C2C12 nuclear FRG1 and conclude 
that FRG1 shuttles between the nucleus and cytoplasm. 
 
FRG1’s subcellular localization changes during myogenic differentiation   
FRG1 is critical for development of the musculature and the vasculature (Hanel et 
al., 2009; Wuebbles et al., 2009); therefore, the newly described subcellular dynamics for 
the endogenous FRG1 were examined during myogenesis (Figure 2.5).  Normal skeletal 
muscle myoblasts were stimulated to undergo differentiation by serum depletion and 
analyzed by ICC at various time points to determine FRG1’s subcellular distribution.  In 
undifferentiated primary myoblasts, FRG1 was almost exclusively cytoplasmic (Figure 
2.5A, B), however within 24 hours of beginning differentiation FRG1 became 
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predominantly nuclear, and strongly nucleolar (Figure 2.5C, D), and by five days post-
differentiation the majority of FRG1 appeared to be predominantly cytoplasmic again, 
although now appearing in stress-fiber-like structures (Figure 2.5E, F).  Interestingly, by 
eight days post-differentiation the cytoplasmic FRG1 appeared in a striated pattern 
reminiscent of sarcomeres with the immunostaining being consistent among all three 
FRG1 antibodies (Figure 2.5G, J, M).  Co-staining for sarcomeric α-actinin showed clear 
co-localization of the striated FRG1 signal with α-actinin (Figure 2.5G-O, arrows), 
indicating that FRG1 was in fact localizing to the sarcomeric structures.  Considering that 
from 2-5 days post-differentiation, α-actinin was aggregating at the sarcolemma (Figure 
2.5D, F), forming Z-disc-like structures in the absence of any detectable localized FRG1, 
we conclude that FRG1 associates with more matured Z-discs, after adjacent myofibrils 
are aligned, and is not likely involved in their establishment or initial assembly. 
 
Sarcomeric FRG1 is associated with the Z-disc 
To determine if FRG1 was a new sarcomere-associated protein, intact mouse 
myofibers were immunostained for FRG1, sarcomeric α-actinin, and desmin (Figure 2.6).  
All three FRG1-specific antibodies showed intense striated patterns of FRG1 (Figure 
2.6A, E, I, M, Q) as well as some nuclear staining (Figure 2.6I, Q, blue arrows) with the 
striated FRG1 immunostaining overlapping with sarcomeric α-actinin (Figure 2.6D, H, 
L).  Higher resolution confocal images revealed the precise co-localization of FRG1 with 
α-actinin (Figure 2.6M-P) however FRG1 and desmin, while displaying highly similar 
patterns, did not precisely co-localize (Figure 2.6Q-T).  Negative controls using secondary 
antibodies alone showed no signal (data not shown).  To further characterize the 
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sarcomeric FRG1, purified myofibrils were immunostained for FRG1, using rhodamine-
phalloidin as a marker for the Z-disc.  Here, FRG1 showed a much more diffuse pattern 
(Figure 2.6U-W) than seen on the intact myofibers suggesting FRG1 is less stably 
associated with the individual myofibrils than the Z-discs of intact myofibers.   
 
DISCUSSION 
Expression analyses have failed to produce consistent, reproducible results 
showing any 4q35 FSHD candidate gene, including FRG1, is misexpressed in FSHD 
muscle biopsies or patient-derived myocytes (Gabellini et al., 2002; Jiang et al., 2003; 
Klooster et al., 2009; Masny et al., 2010; Osborne et al., 2007).  An alternative approach 
using overexpression of FSHD candidate genes in animal models has singled out FRG1 
alone as being able to recapitulate both muscular and vascular FSHD-like pathology when 
overexpressed systemically (Gabellini et al., 2006; Hanel et al., 2009; Liu et al., 2010; 
Wuebbles et al., 2009).  However, these models have been criticized for exaggerated 
levels of expression beyond what would be expected in FSHD and therefore potentially 
leading to artificial phenotypes resulting in an inconclusive verdict.  To gain further 
insight on the viability of FRG1 misexpression being involved in FSHD, we have sought 
here to further understand the endogenous FRG1 protein in mouse muscle and 
differentiating myotubes derived from human skeletal myoblasts.  Although FRG1 is 
ubiquitously expressed in all tissues tested by mRNA analysis (van Deutekom et al., 
1996), our ICC analyses showed the FRG1 protein is specifically localized within 
myotubes and myofibers (Figure 2.5 and 2.6).   Both aspects are interesting from muscle 
development and muscular dystrophy perspectives.   
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Previous cell culture studies using epitope-tagged FRG1 transgenes characterized 
FRG1 as near exclusively nuclear with strong nucleolar and nuclear speckle 
concentrations implicating FRG1 in RNA biogenesis (van Koningsbruggen et al., 2004; 
van Koningsbruggen et al., 2007).  Although our analysis of the endogenous FRG1 in cell 
culture and myofibers clearly contradict the characterization of an exclusive nuclear 
localization for FRG1 (Figure 2.2, 2.3, 2.5, and 2.6), endogenous FRG1 does accumulate 
in the nucleoli during myotube formation supporting the claim for a role in RNA 
biogenesis.  It should be noted than in our nuclear shuttling assays, HA-FRG1 recipient 
cells (HeLa) accumulated the transiently expressed FRG1 almost exclusively in their 
nuclei and specifically in the nucleoli (Figure 2.4), despite the endogenous FRG1 showing 
both cytoplasmic and nuclear staining (Figure 2.2 and 2.3). This data indicates that the 
majority of overexpressed FRG1 protein is nuclear and preferentially nucleolar.  Thus, 
this raises the question of how is the exogenous or overexpressed FRG1 different from the 
endogenously regulated FRG1?  It is interesting to note that different cell types showed 
different ratios of nuclear to cytoplasmic FRG1 with undifferentiated and fully 
differentiated muscle cells showing the greatest amount in the cytoplasm.  Since 
exogenous or overexpressed FRG1 preferentially accumulates in the nucleus, potentially a 
certain cell-type specific level of endogenous FRG1 is capable of being actively 
maintained in the cytoplasm (FRG1 is ~29kDa) at any one time and any increases in 
FRG1 protein levels result in default FRG1 nuclear localization.  Combined with the 
dynamics shown by the nuclear shuttling assays, this would predict that eventually the 
exogenous or overexpressed FRG1 would show the similar cytoplasmic staining albeit 
with the intense nuclear staining, dependent on the turnover rate for the endogenous 
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cytoplasmic retained FRG1.  This is in fact exactly what was seen in the C. elegans study 
on FRG-1; the overexpressed epitope tagged FRG-1 intensely localized to the nuclei yet 
over time, faint but detectable FRG-1 localization was seen in the body-wall muscle 
attachment sites (Liu et al., 2010).  We suggest that in our nuclear shuttling assay and 
published overexpression studies, the overexpressed FRG1 is actively shuttling between 
the nucleus and cytoplasm but is visualized exclusively in the nuclei because it is not 
being readily retained in the cytoplasm.  Conversely, the endogenous FRG1 is stably 
maintained in the cytoplasm awaiting a signal to release it to the nucleus.  This 
cytoplasmic retention model is supported by the dramatic change in endogenous FRG1 
localization to the nucleus in myoblasts upon stimulation of myogenic differentiation 
(Figure 2.5).  This model further predicts that even small changes in FRG1 levels would 
alter its subcellular distribution, aberrantly increasing its levels in the nucleus. 
Active cytoplasmic retention of FRG1 likely involves interaction with other 
proteins to anchor it.  Recently we showed that FRG1 is a bona fide F-actin binding and 
bundling protein (Liu et al., 2010), further supporting a cytoplasmic role for FRG1.  Here 
we have characterized FRG1 as a sarcomeric Z-disc associated protein in mouse and 
myotubes derived from human skeletal myoblasts (Figure 2.5 and 2.6).  This highlights 
that FRG1, although ubiquitously expressed in respect to tissues, has cell type specific, 
and particularly muscle specific, functions.  If FRG1 were misregulated in FSHD, this 
could explain why the genetic lesion presents skeletal muscle specific pathophysiology.  
The Z-disc localization is additionally intriguing in respect to FSHD since in FSHD 
patient muscle some of the structures at the sarcolemma are misaligned and the 
association of the sarcolemma with contractile structures is altered (Reed et al., 2006).  
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Numerous other myopathies can trace their molecular defects to proteins associated with 
the contractile apparatus and force generating structures of skeletal muscle (McNally and 
Pytel, 2007; Selcen, 2008; Selcen and Carpen, 2008).  This work places FRG1 as the only 
current FSHD candidate gene whose product is directly linked to the skeletal muscle 
contractile apparatus. 
Identifying FRG1 as a dynamic nuclear and sarcomere-associated protein may 
suggest a link between the two known biological activities for FRG1, F-actin 
binding/bundling and RNA biogenesis (Liu et al., 2010; van Koningsbruggen et al., 2004; 
van Koningsbruggen et al., 2007).  Potentially FRG1 could be transducing signals from 
the Z-disc to the nucleus directly and affecting mRNA biogenesis, as is the case for the 
dynamic Z-disc protein MLP (Arber et al., 1994; Knoll et al., 2002).  Conversely, FRG1 
may be involved in trafficking molecules such as RNAs to the Z-disc for site-specific 
translation.  In either case, one can imagine how aberrantly altering the levels of FRG1, 
and thus affecting FRG1-mediated signaling or transport, could disrupt the efficiency of 
myogenic differentiation, muscle regeneration, and maintenance of muscle integrity over 
time as seen in the animal models overexpressing or depleting FRG1, and as proposed for 
FSHD (Wuebbles et al., 2009). 
Overall, we identify FRG1 as a dynamic nuclear and cytoplasmic protein 
associated with mature sarcomeres in mouse skeletal muscle and myotubes derived from 
human skeletal myoblasts. Thus, FRG1, an actin-bundling protein previously shown to be 
critical for muscle and vascular development, provides the only link between a FSHD 
candidate gene and the muscle contractile machinery. 
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MATERIALS AND METHODS 
Cell culture   
HeLa cells and C2C12 cells were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) containing 10% fetal bovine serum (FBS) 2 mM L-glutamine, and 1% 
penicillin–streptomycin (pen/strep).  Proliferating primary human skeletal muscle 
myoblasts (HSMM) were obtained from Lonza (Walkersville, MD) and were seeded on 
0.02% collagen-coated surfaces and maintained in SkBM-2 medium supplemented with 
SkGM-2 SingleQuots (Lonza) according to the manufacturer’s instructions.  For myotube 
formation, HSMMs were seeded on 0.02% collagen-coated coverslips at 1.5 x 104/cm2 
density for ICC analysis, and the following day were induced to form myotubes by adding 
fusion medium (DMEM/F-12 50:50 supplemented with 2% horse serum).  Murine muscle 
derived stem cells (MDSC) were isolated and cultured as described (Qu-Petersen et al., 
2002).  For ICC analysis, MDSCs were seeded on 0.02% collagen-coated coverslips. 
 
Preparation of myofibers   
Mice (C57/B6) were humanely euthanized in accordance with approved UIUC 
IACUC protocols. Adult mouse muscle fibers were isolated from the flexor digitorum 
brevis muscle of 1-3 month old female mice.  Isolated muscles were washed briefly in 
DMEM, then incubated in DMEM with 0.2% collagenase type I (Worthington 
Biochemical, Lakewood, NJ) for 4 hrs at 37°C, with gentle agitation every 15 min and 
changes into fresh collagenase solution every hour. At the completion of digestion, excess 
tendon material was carefully dissected away, and fiber bundles were transferred to a dish 
of myofiber medium (DMEM supplemented with 10mM HEPES, 5% heat-inactivated 
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horse serum, 1% pen/strep and 0.1% amphotericin B).  Individual fibers were liberated 
from the muscle mass by gentle tituration and agitation, and cultured overnight in 
myofiber medium at 37°C, 5%CO2.  The following day, healthy, undamaged myofibers 
were plated on glass coverslips coated with Geltrex (Invitrogen, Carlsbad, CA) and 
allowed to adhere for 1-2 hrs before fixation.   
 
Preparation of myofibrils   
Myofibrils were prepared as described (Qu-Petersen et al., 2002).  Skeletal muscle 
was dissected from rectus femoris muscle, teased into thin 3-5 mm strips, and soaked in 
EGTA-Ringer’s solution (100 mM NaCl, 6 mM KH2PO4, 2 mM KCL, 2 mM MgCl2, 1 
mM EGTA, 0.1% glucose, pH 7.0 at 0°C) overnight at 4°C.  Muscle strips were 
transferred to ice-cold rigor buffer (100 mM KCl, 2 mM MgCl2, 10 mM KH2PO4, 1 mM 
EDTA, 0.5 mM DTT, pH 7.0 at 0°C) and homogenized using a loose pestle Dounce tissue 
grinder until a majority of individual myofibrils were obtained by observing under a phase 
contrast microscope.  The homogenate was centrifuged at 200xg for 5 min to remove 
debris and the supernatant was centrifuged at 2000xg for 5 min to pellet myofibrils. The 
myofibrils were washed 5 times with ice-cold rigor buffer, plated on coverslips coated 
with poly-L-lysine, and immediately fixed for immunofluorescence staining. 
 
Protein extracts 
To generate whole cell extracts (WCE), cells were collected in PBS, pelleted, 
resuspended in 10 cell volumes of RIPA+ buffer (150 mM NaCl, 1% IGEPAL, 0.5% 
sodium deoxycholate, 50 mM Tris pH 8.0, + 1% SDS), and incubated on ice for 10 min.  
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Lysed cells were sonicated briefly, centrifuged at 100,000xg for 10 min and the soluble 
fraction was used for western blotting analysis.  Nuclear and cytoplasmic fractions were 
generated as described (Shapiro et al., 1988). The PCNA rabbit monoclonal antibody 
(Epitomics, Inc, 2755-1) was used as marker for the nuclear fraction. 
 
FRG1 antibodies 
The HS1, HS2, and DM1 rabbit polyclonal antibodies were made by GenScript 
USA Inc. (Piscataway, NJ) and generated against synthesized peptide antigens conjugated 
to KLH.  The HS1 peptide (KKDDIPEEDKGNVK) and HS2 peptide 
(GRSDAIGPREQWEP) were from the predicted human FRG1 amino acid sequence 
while the DM1 peptide (TLLDRRSKMKADRYC) was from the predicted Drosophila 
melanogaster FRG1 (CG6480) amino acid sequence (Figure 2.1).  Antisera were affinity 
purified against the peptide cross-linked to NHS-Sepharose (GE Healthcare), eluted in 10 
mM glycine, pH 2.5, and dialyzed against PBS pH7.4.  
 
FRG1 siRNA knockdown 
The On-Target plus SMARTpool siRNA reagent for human FRG1 (Dharmacon, 
Inc) containing four duplex siRNAs (siRNA1: GUUUACGGCUGUCAAAUUA; 
siRNA2: CGACAGAUACUGCAAGUGA; siRNA3: GGAACCAAGACGAAGAGUA; 
siRNA4: AAACCCAGCUUGAUAUUGU) was used for FRG1 knockdown in cell 
culture.  Transfections were carried out using oligofectamine (Invitrogen) at a final 
concentration of 100 nM siRNAs.  HeLa cells (~50% confluent) were transfected three 
times in 24 hr intervals and then assayed for FRG1 by ICC. 
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Nuclear shuttling assay 
The assay was carried out essentially as described (Kawamura et al., 2002).  The 
HA-FRG1 expression plasmid was generated by subcloning the human FRG1 coding 
sequence into pcDNA3.1 HA (Matzat et al., 2008). Murine C2C12 cells (~60% confluent) 
were transfected with pcDNA3.1HA-FRG1 using TransIT-LT1 reagent (Mirus Bio LLC, 
Madison, WI) and allowed to grow for 24 hrs.  The cells were removed by trypsinization, 
washed with PBS, plated on poly-L-lysine coated coverslips (1 x 105/cm2) and allowed to 
adhere for 2 hrs before non-transfected HeLa cells were overlaid (5 x 104/cm2) onto the 
transfected C2C12 cells for 3 hours.  The co-cultures were incubated with 100mg/ml 
Cycloheximide (CHX) for 15 min to stop translation, and the cells were fused by adding 
50% (wt/vol) polyethylene glycol 4000 in DMEM for 2 min.  The fusions were 
immediately washed with DMEM and then incubated with 100mg/ml CHX for 2, 3, or 4 
hrs followed by ICC analysis. The cells were fixed with 4% formaldehyde (FA) in PBS 
for 15 min, immunostained with HA monoclonal antibody clone 3F10 (1:100)(Roche) as 
described below, and co-stained stained with Hoechst 33342 (5 mg/ml in PBS). 
 
ICC staining 
HeLa, C2C12, and MDSC, were fixed in 4% FA in PBS and HSMM were fixed in 
2% FA in PBS, for 15 min at room temperature (RT). After fixation, cells were 
permeabilized with 0.25% Triton-X 100 in PBS for 10 min on ice, and subsequently 
blocked with 2% BSA in PBS for 30 min at RT. Primary antibody incubations were 
carried out at RT for 1 hr up to overnight at 4°C and secondary antibody incubations were 
for 40 min at RT.  Mouse myofibers were fixed in 2% paraformaldehyde for 15 minutes, 
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rinsed with PBS and permeabilized with 0.1% Triton X-100 for 10 min.  For blocking, 
fibers were incubated in TBS-T +5% milk powder and 0.02% sodium azide for 1 hr at RT, 
or alternatively, overnight at 4oC, and then incubated with diluted primary antibodies and 
secondary antibodies as above.  Mouse myofibrils were fixed with 2% FA in PBS for 15 
min at RT, rinsed with PBS and permeabilized with 0.1% Triton X-100 for 10 min.  
Myofibrils were blocked with normal goat serum for 30 min at RT then incubated with 
FRG1 primary antibody followed by Alexa 488-conjugated goat anti-rabbit IgG secondary 
antibody as described above.  The antibodies and their dilutions were as follows: desmin 
monoclonal antibody [D9] (Santa Cruz Biotechnology Inc, sc-52326), 1:1000; sarcomeric 
α-actinin mouse monoclonal antibody [EA-53] (Abcam Inc, ab-9465), 1:200; FRG1 HS1 
(1:100), HS2 (1:200), and DM1(1:200).  Secondary antibodies used were FITC-
conjugated goat anti-mouse, FITC-conjugated donkey anti-rabbit (pre-cleared), and 
rhodamine-conjugated goat anti-rabbit (Jackson ImmunoResearch Laboratories Inc) used 
at 1:100.  Alexa488-conjugated goat anti-rabbit IgG, highly absorbed (Invitrogen) used at 
1:800. F-actin was visualized with 5 units/ml rhodamine-phalloidin (Invitrogen) incubated 
for 30 min at RT for cell culture staining, and with 1 unit/ml rhodamine-phalloidin 
incubated for 2 min at RT for myofibrils. DAPI was used at 1µg/ml. 
 
Microscopy 
Fluorescence mages were taken by fluorescence microscopy using an Olympus 
BX60 microscope equipped with a SpotRT monochrome model 2.1.1 camera and Spot 
Advanced software (Diagnostic Instruments, Sterling Heights, MI).  Confocal microscopy 
was carried out with Zeiss LSM510.  Immunohistochemical images were acquired with 
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Olympus BX60 microscope equipped with a Leica DFC290 camera using Leica 
Application Suit software (Leica microsystems). All images were processed using Adobe 
Photoshop to adjust brightness, contrast, size, and merged or split channels. 
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FIGURES 
 
 
Figure 2.1: FRG1 is highly conserved from human to C. elegans.  A ClustalW 
sequence comparison of the predicted amino acid sequences for the human, mouse, 
Xenopus laevis, Drosophila melanogaster, and Caenorhabditis elegans FRG1 homologs.  
The location of FRG1 antibodies used in this study are shown and highlighted in yellow.  
The highlighting indicates species cross-reactivity and amino acid differences are shown 
in bold red lettering. NLS = nuclear localization signal. 
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Figure 2.2: FRG1 antibodies are highly specific.  Immunocytochemistry on HeLa cells 
(A, B, E, F, I, J) or HeLa cells transfected with a FRG1-specific pool of siRNAs (C, D, G, 
H, K, L) using the HS1 (A-D), HS2 (E-H), or DM1 (I-J) FRG1 antibodies show a specific 
reduction in both the cytoplasmic and nuclear FRG1 antibody signal intensities in the 
siRNA treated cells.  The merged images (B, D, F, H, J, L) show FRG1 (A, C, E, G, I, K) 
in green, DAPI in blue, and phalloidin in red.  Images are taken under the same 
parameters. Bars = 10 µm.  M) Western blot analysis of HeLa whole-cell extract (200 
mg/lane) probed with HS1, HS2, and DM1 as indicated.  PS indicates Ponceau S staining 
of membranes. N) Western blot analysis of HeLa cell extract fractionated into nuclear and 
cytoplasmic pools and probed with DM1 and HS2 as indicated.  A monoclonal antibody 
against proliferating cell nuclear antigen (PCNA) was used to control for contamination of 
the cytoplasmic protein pool with nuclear proteins. 
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Figure 2.3:  Endogenous FRG1 is both a nuclear and cytoplasmic protein in multiple 
cell types.  Immunocytochemistry on cultured (A-L) HeLa cells, and (M-P) murine 
C2C12 cells reveal intense nuclear FRG1 immunostaining accompanied by cytoplasmic 
FRG1 immunostaining (A, E, I, M; green in merge). (Q-T) Human skeletal muscle 
myoblasts, and (U-X) murine muscle-derived stem cells show much more prominent 
cytoplasmic FRG1 immunostaining (Q, U, T, X; green in merge). Rhodamine-phalloidin 
staining (B, F, J, N; red in merge) labeled the cytoplasmic actin filaments while DAPI (C, 
G, K, O, S, W; blue in merge) labeled nuclei.  Desmin immunostaining (R, V; red in 
merge) was used to confirm the myoblast phenotypes.   
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Figure 2.3 continued: (U-X) White arrow indicates a desmin negative MDSC and blue 
arrow indicates a desmin positive MDSC beginning differentiation.  Overall, the 
immunostaining patterns within a cell type are consistent between HS1 (A-D, Q-T), HS2 
(E-H), and DM1 (I-L, M-P), three independent FRG1 antibodies raised against peptides 
from different regions of FRG1, as shown in Figure 2.1. Bars = 10 µm. 
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Figure 2.4: FRG1 shuttles between the nucleus and cytoplasm.  (A-L) Murine C2C12 
cells, morphologically distinguished by their DAPI-bright foci (white arrow), expressing 
HA-FRG1 (red) and treated with cyclohexamide (CHX) were fused with HeLa cells, 
distinguished by their DAPI-poor nucleoli (blue arrows) in the presence of CHX.  (A-D) 
Two hours into the fusion process FRG1 translated in the C2C12 cells begins to localize 
in the HeLa cell nuclei (C’, longer exposure of C) and specifically the nucleoli (D, blue 
arrows).  This translocation of FRG1 from C2C12 to HeLa nuclei is more evident at 3 
hours (E-H) and at 4 hours (I-L), appearing to have reached equilibrium between the two 
cell type nuclei (K). Bars = 10 µm. 
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Figure 2.5:  FRG1 subcellular localization changes dramatically when primary 
human skeletal myocytes are stimulated to undergo myogenic differentiation.  FRG1 
subcellular localization was monitored using the HS1 antibody (A-I red) in normal human 
skeletal muscle myoblasts (A, B), 2 days post-differentiation (C, D), 5 days post-
differentiation (E, F), and 8 days post-differentiation (G-I).  Developing Z-discs were 
monitored by α-actinin immunostaining (D, F, I, L, O; green).  FRG1 was similarly 
monitored with the HS2 (J-L; red) and DM1 (M-O; red) antibodies with only the 8 days 
post-differentiation shown.  Using all three antibodies FRG1 is detected co-localized with 
α-actinin at Z-discs 8 days post-differentiation, but not earlier (I, L, O; white arrows).  
Desmin immunostaining (B; green) confirmed the myoblast phenotype and DAPI 
identified the nuclei (B, D, F; blue).  Bars = 10 µm. 
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Figure 2.6:  FRG1 is a sarcomeric protein localized to myofiber Z-discs.  To 
characterize FRG1’s localization at the sarcomere, mouse muscle fibers were isolated and 
subjected to immunohistochemistry using the HS1 (A, M, Q), HS2 (E) and DM1 (I) FRG1 
antibodies and co-staining for α-actinin (B, F, J, N) or desmin (R).  Images were 
visualized by standard fluorescent microscopy (A-L) or by fluorescent confocal 
microscopy (M-T). When merged (D, H, L,) α-actinin (green) appears overlapping and 
flanked by the FRG1 (red) around the Z-lines. However, confocal images clearly show the 
precise co-staining of FRG1 and α-actinin (O, P) while FRG1 and desmin only partially 
overlap (S, T).  In all cases, FRG1 was detectable in myofiber nuclei (blue arrows). Bars = 
10 µm.  (U-W) Isolated myofibril immunostained with HS1 (U), counter stained with 
rhodamine-phalloidin (V), and images merged (W).  Bar = 10 µm.  
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CHAPTER 3* 
 FRG1 IS A RNA­ASSOCIATED PROTEIN 
* Some of the data and writing is adapted from 
 
 Chia-Yun Jessica Sun, Silvana van Koningsbruggen, Kirsten Straasheijm, Rinse Klooster, Steven 
W. Long, Takako I. Jones, Michel Bellini, Lyne Levesque, William M. Brieher, Silvère M. van der Maarel, 
and Peter L. Jones. FSHD region gene 1 (FRG1) is a dynamic RNA-associated, actin bundling protein. 
Submitted for publication.  
INTRODUCTION 
FSHD region gene 1 (FRG1) is a dynamic nuclear and cytoplasmic protein that, in 
skeletal muscle, shows an additional localization to the sarcomere as described in Chapter 
2.  FRG1 is required for the normal development of the vertebrate musculature and 
vasculature and overexpressing FRG1 in vertebrate and invertebrate animal models leads 
to muscular dystrophy (Gabellini et al., 2006; Hanel et al., 2009; Liu et al., 2010; 
Wuebbles et al., 2009), however, the precise function of the endogenous human FRG1 is 
unknown.  A putative domain analysis of the predicted FRG1 protein sequence revealed 
two nuclear localization signals (NLS) residing in the N-terminus, one bipartite NLS in 
the C-terminus, and a central fascin-like domain, found in the fascin family of actin-
bundling and cross-linking proteins (Kureishy et al., 2002).  Overall, FRG1 in its entirety 
is very highly conserved from vertebrates to invertebrate (human FRG1 shares 97%, 81%, 
and 46% homology with mouse, Xenopus, and C. elegans, respectively) suggesting 
important biological functions that were conserved throughout evolution (Grewal et al., 
1998). 
Several lines of evidence suggest FRG1 is involved in RNA biogenesis. Epitope-
tagged FRG1 overexpressed in vertebrate cell culture appears almost completely nuclear, 
and localized to the nucleoli, Cajal bodies, and nuclear speckles, sites where RNA-
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biogenesis is taking place (van Koningsbruggen et al., 2004).  Mis-spliced mRNA 
transcripts were found in U2OS cells overexpressing FRG1 as well as transgenic mice 
overexpressing FRG1, implicating FRG1 is involved in alternative splicing (Gabellini et 
al., 2006; van Koningsbruggen et al., 2007).  Biochemically, FRG1 has been found to 
associate with RNA processing components and large-scale proteomic studies revealed 
that FRG1 is associated with human spliceosome complex (Rappsilber et al., 2002; van 
Koningsbruggen et al., 2007).  Interestingly, two potential FRG1-associating proteins, 
which are RNA processing components, SMN and PABPN1, are themselves involved in 
neuromuscular disorders (Brais et al., 1998; Briese et al., 2005; Calado et al., 2000). 
FRG1, due to its location 125 kb centromeric to the genetic lesion of FSHD, the 
D4Z4 repeats, is one of the early candidate genes (van Deutekom et al., 1996).  However, 
expression levels of FRG1 in muscle biopsies, primary myoblasts and myotubes derived 
from FSHD patients have varied from 25-fold increased, unchanged, and 5-fold decreased 
compared with controls (Arashiro et al., 2009; Gabellini et al., 2002; Jiang et al., 2003; 
Klooster et al., 2009; Masny et al., 2010; Osborne et al., 2007; Winokur et al., 2003). Any 
role for FRG1 in FSHD pathogenesis is further complicated by our lack of understanding 
of the normal function of FRG1 in muscle development. 
We have previously shown that FRG1 is a dynamic nuclear and cytoplasmic 
protein in Chapter 2.  This chapter will further investigate the cellular localization of 
endogenous human FRG1 and focus on the nuclear aspects of human FRG1 biology in 
respect to RNA biogenesis.  We further characterized the FRG1 nuclear and nucleolar 
localizations and identified FRG1 RNA association in vitro and in vivo, and show that 
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FRG1 is a dynamic nuclear-cytoplasmic shuttling protein that interacts with TAP, a 
nuclear RNA export protein.  
 
RESULTS 
Endogenous human FRG1 is both nuclear and cytoplasmic, and is prominently localized 
to the granular component of nucleoli 
In order to characterize the endogenous human FRG1, HeLa cells were subjected 
to immunocytochemistry using the highly specific HS1 FRG1 antibody described in 
Chapter 2 (Figure 3.1).  In contrast to the exclusively nuclear localization often seen for 
overexpressed, epitope-tagged FRG1 (van Koningsbruggen et al., 2004), the endogenous 
HeLa FRG1 exists in both nuclear and cytoplasmic pools.  Consistent with previous data 
for the overexpressed FRG1, the endogenous nuclear FRG1 is prominently localized in 
the DAPI-poor foci (Figure 3.1A-C).  Co-immunostaining for FRG1 and fibrillarin, a 
nucleolar marker (Aris and Blobel, 1991) showed the endogenous FRG1 concentrates in 
the nucleoli (Figure 3.1D-G), however, the nucleolar FRG1 associated with but did not 
completely co-localize with fibrillarin (Figure 3.1D-G) suggesting that nucleolar FRG1 
was not part of the dense fibrillar component (DFC).  The DFC and granular center (GC) 
of the nucleolus can be readily distinguished from each other by inhibition of RNA 
polymerase I transcription using Actinomycin D (AMD) (Olson and Dundr, 2005).  HeLa 
cells treated with AMD showed FRG1 localized to the GC, distinctly separate from the 
DFC marked by fibrillarin  (Figure 3.1H-K).  Beyond the nucleolar localization, FRG1 
showed punctate nuclear immunostaining suggestive of nuclear speckles (Figure 3.1E, I, 
M), therefore, HeLa cells were co-immunostained for FRG1 and the nuclear speckle 
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marker SC35 (Spector et al., 1991).  FRG1 did not co-localize with SC35 indicating it is 
not a part of SC35-containing nuclear speckles (Figure 3.1L-O). 
 
Endogenous FRG1 associates with nascent RNA transcripts in vivo 
FRG1 was previously implicated in aspects of RNA biogenesis, in particular pre-
mRNA splicing.  It is currently well accepted that most RNA processing factors are 
recruited to nascent transcripts co-transcriptionally, resulting in the formation of export-
competent ribonucleoprotein (RNP) complexes at the sites of transcription.  Many of these 
factors, such as the heterogenous nuclear ribonucleoprotein G (hnRNP G) were shown to 
associate with most transcription units of RNA polymerase II (RNAPII) in amphibian 
oocytes (Morgan, 2002; Soulard et al., 1993).  Chromatin in Xenopus laevis oocytes is 
structured within lampbrush chromosomes (LBC) and several thousand non-chromosomal 
nucleoli.  LBCs are often described as extended diplotene bivalent chromosomes, and 
their characteristic shape is the result of the intense transcriptional activity that is 
associated with them.  Each homologue consists of a condensed chromatin axis, from 
which are escaping numerous pairs of lateral loops that are active transcription units of 
RNAPII.  Although the chromatin of these loops almost certainly adopts the conformation 
of a 10nm (or less) fiber (Morgan, 2002), they are readily distinguishable by light 
microscopy because the chromatin axis is surrounded by a dense matrix of nascent RNP 
fibrils.  We took advantage of this unique spatial resolution to test whether FRG1 
associates with nascent transcripts, using an antibody specific for X. laevis FRG1 (Hanel 
et al., 2009) on nuclear spreads (Figure 3.2).  Endogenous FRG1 is detected within the 
RNP matrix of the LBC loops (Figure 3.2E-L), which provides strong evidence that FRG1 
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interacts with nascent transcripts within the cell nucleus.  In addition, FRG1 is also found 
associated with Cajal bodies, nucleoli and the nuclear speckles (or interchromatin granule 
clusters) (Figure 3.2A-D), which is consistent with the subnuclear distribution of FRG1 
defined previously in human cells and further support a role of FRG1 in RNA biogenesis 
(van Koningsbruggen et al., 2004). 
 To determine if the endogenous human FRG1 associates with human mRNAs in 
vivo, RNA immunoprecipitations (RIP) were performed on HeLa whole cell extracts using 
the HS1 FRG1-specific antibody previously characterized (M. L. Hanel, submitted for 
publication).  After the RIP procedure, FRG1 associated RNAs were subjected to reverse 
transcriptase PCR (RT-PCR), initially assaying for FXR1, a transcript known to be 
affected in FSHD (Davidovic et al., 2008) (Figure 3.3, lanes 2 and 6).  All RIP RT-PCR 
products were sensitive to RNase A treatment of the starting material confirming the RNA 
(and not DNA) association (Figure 3.3, lanes 7 and 9).  Furthermore, a RIP non-specific 
antibody control, affinity-purified PAT-9 antiserum was used and failed to IP any 
detectable RNAs illustrating the specificity of the RIP procedure for FRG1 (Figure 3.3, 
lane 3).  Subsequently, RIP reactions were assayed by RT-PCR for the FRG1 and HPRT 
mRNAs, all producing results similar to that shown for FRX1 (data not shown).  Although 
it is not clear if the FRG1-RNA association is direct or indirect, these results show that 
endogenous human FRG1 associates with numerous mRNA transcripts in vivo. 
 
Recombinant human FRG1 interacts with RNA directly 
Although FRG1 does not contain any conventional RNA-binding motif, many 
RNA associated ribonucleoproteins (RNPs) interact with RNA directly in vitro (Dreyfuss 
  56 
et al., 2002; Dreyfuss et al., 1993).  To determine if FRG1 is capable of binding with RNA 
directly, RNA electrophoretic mobility shift assays (REMSA) were performed using 
recombinant human FRG1 or deletion mutants of FRG1 (Figure 3.4A and B) and 
radiolabeled, in vitro transcribed Xenopus β-globin RNA as a probe.  Full-length FRG1 
formed a protein-RNA complex as indicated by the FRG1-dependent slower migrating 
RNA species (Figure 3.4C, lanes 2-4).  Since there is no predicted RNA binding domain 
described for FRG1, recombinant proteins from four deletion constructs were used for 
REMSA to identify the FRG1 RNA-binding domain.  The results showed that FRG1 
binds RNA directly through its N-terminal NLS as deleting this region abolishes the 
RNA-binding activity of FRG1 (Figure 3.4C, lanes 14-16) while the other three deletions 
maintained RNA-binding activity similar to full-length FRG1.  To determine if this 
interaction was specific to RNA, competition assays were performed using in vitro 
transcribed but unlabeled RNA probe as a specific competitor, and tRNA and double 
stranded (ds) DNA as query competitors.  The FRG1-RNA interaction was successfully 
competed by the addition of cold RNA probe (Figure 3.4D, lanes 6-9) and tRNA (Figure 
3.4D lanes 10-13), however, dsDNA did not compete (Figure 3.4D, lanes 14-17) 
indicating that the FRG1-nucleic acid interaction is specific to RNA. 
 
FRG1 shuttling is dependent on RNA polymerase II-mediated transcription 
FRG1 has been shown to shuttle between the nucleus and cytoplasm in Chapter 2, 
and to associate with mRNAs (Figures 3.2-4), therefore the effect of transcription 
inhibition on FRG1’s nuclear shuttling was investigated by heterokaryon assay (Figure 
3.5).  Transfected HeLa cells, readily identified by Hoechst staining as containing large 
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DNA-poor nucleoli (Figure 3.5, blue arrows), that transiently express HA-FRG1 were 
fused to non-transfected C2C12 cells, easily identified by the multiple DNA-bright foci 
(Figure 3.5, white arrows), in presence of cycloheximide (CHX) blocking de novo 
translation.  Overexpressed HA-FRG1 in the HeLa cells showed exclusive nuclear 
localization with enrichment at nucleoli as reported previously (van Koningsbruggen et 
al., 2004).  Three hours after fusion was initiated, HA-FRG1 staining was detected in 
C2C12 nuclei (Figure 3.5A-D), and this shuttling was not affected by Leptomycin B 
(LMB), an inhibitor of the CRM1/exportin1 nuclear export pathway (Figure 3.5E-H 
compared with A-D, CHX alone).  These results indicate FRG1 nuclear export occurs 
through a CRM1 independent pathway. We further investigated an effect of the 
transcription on FRG1 shuttling.  Treatment with low levels of AMD (0.4 mg/ml) had no 
apparent effect on FRG1 shuttling or nucleolar localization in HeLa cells (Figure 3.5I-L); 
however, treatment with a higher dose of AMD (5 µg/ml), inhibiting all three RNA 
polymerases, resulted in FRG1 being excluded from HeLa nucleoli and appeared 
consistently to be preferentially accumulated into the nuclei of recipient C2C12 cells 
(Figure 3.5M-P).  These data suggest FRG1 nuclear export is somehow linked to RNA 
polymerase II-mediated transcription. 
 
FRG1 interacts with the nuclear export protein TAP 
Considering FRG1 binds RNA in vitro, associates with mRNA in vivo, and its 
nuclear shuttling depends on RNA polymerase II transcription, it seemed reasonable that 
FRG1 might be involved in mRNA export as part of a hnRNP complex.  Since the 
majority of mature mRNAs in the nucleus are exported through the TAP/NXT1 pathway, 
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FRG1 was tested for a direct interaction with TAP in vitro (Figure 3.6).  GST pull-down 
assays were performed using recombinant GST-TAP and radiolabeled in vitro transcribed 
and translated (TnT) full-length human FRG1 and FRG1 deletion constructs. The results 
showed that FRG1 interacts directly with TAP mediated through the FRG1 N-terminal 
NLSs (Figure 3.6A).  Since both TAP and FRG1 interact with RNA, and RNA could be 
present from the recombinant protein purification or TnT reaction, the GST pull-down 
assay was repeated with benzonase nuclease to digest any RNA or DNA.  Benzonase 
nuclease treatment did not affect the FRG1-TAP interaction indicating that FRG1 interacts 
with TAP directly and independent of RNA (Figure 3.6B). 
 
DISCUSSION 
FRG1 is critical for development of the vertebrate musculature and vasculature 
and has been implicated in mediating FSHD pathophysiology.  Still, very little is known 
about FRG1, hindering our understanding of how changes in its expression levels might 
lead to disease.  In this Chapter, we further investigated human FRG1 by characterizing its 
subcellular localizations, biological activities and identifying new interacting proteins. 
Experiments were performed to determine the biological function of nuclear 
FRG1.  The nuclear fraction of endogenous FRG1 is concentrated in Cajal bodies (CBs) 
and the granular component (GC) of nucleoli, as well as associated with nascent mRNA 
transcripts and the actively transcribed regions of the euchromatin.  The CBs are nuclear 
bodies rich in factors involved in transcription and RNA processing and are sites of 
snRNP biogenesis (Austin and Bellini, 2010; Gall, 2003).  Thus, FRG1’s presence in CBs 
is consistent with its proposed role in RNA biogenesis and provides additional similarity 
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with RNPs (Rappsilber et al., 2002; van Koningsbruggen et al., 2004; van 
Koningsbruggen et al., 2007).  Similarly, FRG1’s nucleolar localization supports these 
functional roles.  Nucleoli, the dynamic structures containing tandem chromosomal 
repeats encoding rRNAs, are sites where pre-ribosomal particles are transcribed and 
assembled; however, nucleoli have additional roles including maturation of some RNP 
particles, assembly of the RNA splicing machinery, and sequestration of certain nuclear 
regulatory factors (Austin and Bellini, 2010; Boisvert et al., 2007).  FRG1’s nucleolar 
localization to the GC and not with either fibrillar component suggests FRG1 is involved 
in later stages of rRNA processing and not directly with rDNA transcription (Sirri et al., 
2008).  In addition to the rRNA co-localization, both lampbrush chromosome spreads and 
RNA-IPs from HeLa cells indicate that the endogenous FRG1 associates with nascent 
RNA polymerase II generated mRNAs in vivo.  However, although FRG1 is capable of 
directly interacting with RNA in vitro, and is in a complex with mRNA in vivo, it is not 
clear that in vivo its RNA association is mediated directly through FRG1.  Interestingly in 
FSHD-derived muscle cells, the muscle-specific isoforms of FXR1, a target of FRG1, 
show an aberrant expression pattern due to decreased mRNA stability (Davidovic et al., 
2008) while the mRNAs from fast skeletal muscle troponin T (TNNT3) and myotubularin 
related protein 1 (MTMR1) show aberrant alternative mRNA splicing (Gabellini et al., 
2006).   
Many RNA-binding proteins are involved in pre-mRNA processing as well as the 
transport, localization, translation and the stability of mRNAs (Dreyfuss et al., 2002).  
Based on our data showing the endogenous FRG1 is both nuclear and cytoplasmic, 
associates with mRNAs, and is a nuclear shuttling protein, we thus hypothesized that 
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FRG1 might function in the nuclear to cytoplasmic transport of mRNAs.  We found that 
FRG1 interacts directly with TAP/NXF1, a member of the NXF family of transport 
receptors (Gruter et al., 1998).  TAP-NXT1 heterodimers associate with RNA-binding 
adaptor proteins in the nucleus to mediate the nuclear export of the majority of mature 
mRNAs through the nuclear pore complex (NPC).  Together with previous data 
identifying FRG1 as a component of the spliceosome (Rappsilber et al., 2002), these data 
support a role for FRG1 in several aspects of RNA biogenesis, including RNA splicing 
and RNA transport. 
 
MATERIALS AND METHODS 
DNA constructs 
All PCR primers are listed in Table 3.1.  To generate the FRG1 His-tagged 
bacterial expression constructs, the cDNA for the full-length human FRG1 coding 
sequence was PCR amplified (primers #1 and #2) and subcloned between the NdeI and 
XhoI restriction sites into pET-23b vector (Novagen, Gibbstown, NJ).  The pET-FRG1 
deletion constructs were made by the same procedure with the following primer sets: #2 
and #3 for (Δ1-32), #2 and #4 for (Δ1-20), #1 and #5 for (Δ235-258), and #1 and #6 for 
(Δ183-258). 
 
Cell culture 
HeLa, and C2C12 cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 2 mM L-glutamine, supplemented with 10% fetal bovine serum 
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(FBS) and 1% penicillin–streptomycin (pen/strep).  Cells were incubated with 5% CO2 at 
37°C. 
 
Antibodies 
Four rabbit polyclonal antibodies were used, all raised against synthetic peptides 
corresponding to human FRG1.  The HS1 (NH2-CKKDDIPEEDKGNVK) and HS2 (NH2-
CGRSDAIGPREQWEP) FRG1 antibodies were generated by GenScript USA Inc. 
(Piscataway, NJ), and antisera were affinity purified against the peptide cross-linked to 
NHS-Sepharose (GE Healthcare, Piscataway, NJ), eluted in 10 mM glycine, pH 2.5, 
dialyzed against PBS pH7.4, and characterized in Chapter 2. 
 
Immunocytochemistry 
HeLa cells were fixed in 2% formaldehyde (FA) in PBS for 15 min at room 
temperature (RT).  After fixation, cells were made permeable with 0.25% Triton-X 100 in 
PBS for 10 min on ice, and subsequently blocked with 2% BSA in PBS for 30 min at RT. 
Primary antibody incubation was carried out overnight at 4°C in PBS with 2% BSA, and 
secondary antibody incubation was for 40 min at RT in PBS.  Co-staining experiments 
were performed using FRG1 HS1, mouse monoclonal fibrillarin (ab18380, Abcam, 
Cambridge, MA) and SC-35 (S4045, Sigma-Aldrich, St. Louis, MO) antibodies at 1:500, 
1:100 and 1:200 dilutions, respectively.  Secondary antibodies used were FITC-
conjugated donkey anti-rabbit (pre-cleared) and rhodamine-conjugated goat anti-mouse, 
or rhodamine-conjugated goat anti-rabbit and FITC-conjugated goat anti-mouse (Jackson 
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ImmunoResearch Laboratories Inc) used at 1:100.  The 4,6-diamidino-2-phenylindole 
(DAPI) was used at 1µg/ml. 
  
Lampbrush chromosome spreads 
Female adult frogs (Xenopus laevis) were anesthetized in 0.15% tricaine 
methanesulfonate (Sigma-Aldrich), and small fragments of ovary were surgically 
removed. Oocytes were defolliculated for 1 hr in saline buffer OR2 (Wallace et al., 1973) 
containing 0.15% collagenase type II (Sigma-Aldrich).  Stage IV-V oocytes were selected 
and maintained in OR2 at 18˚C.  Nuclear spreads were prepared as described (Patel et al., 
2007). Fixed nuclear spreads were rinsed in PBS and blocked in PBS containing 0.5% 
bovine serum albumin (Sigma-Aldrich) plus 0.5% gelatin (from cold-water fish). Spreads 
were incubated with primary antibody, XTB-FRG1 (Hanel et al., 2009), for 1 hr at RT, 
washed for 30 min with two changes of PBS, incubated with secondary antibody Alexa 
488 conjugated goat anti-rabbit antibody (Invitrogen Corp.) for 1 hr at RT, and washed 
again for 30 min with two changes of PBS. Spreads were mounted in 50% glycerol 
containing 1mg/ml phenylenediamine and 10 pg/ml DAPI. 
 
Nuclear shuttling assay 
The assay was carried out essentially as described (M. L. Hanel, submitted for 
publication). HeLa cells (~60% confluent) were transfected with pcDNA3.1HA-FRG1 
(M. L. Hanel, submitted for publication) using TransIT-LT1 reagent (Mirus Bio, Madison, 
WI) and allowed to grow for 24 hrs.  The cells were removed with trypsin, washed in 
PBS, plated (1 x 106) on glass coverslips and allowed to adhere for 2 hrs before non-
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transfected murine C2C12 cells (5 x 105) were overlaid onto the transfected HeLa cells for 
3 hours.  Translation was stopped with cycloheximide (CHX) (100 µg/ml) treatment for 
15 min prior to fusion.  After removing the media, cells fused by adding 50% PEG 4000 
in DMEM for 2 min.  The fusions were immediately washed with DMEM and then 
incubated for three hours in the presence of CHX (100 µg/ml), CHX (100 µg/ml) + 
actinomycin D (AMD) (0.4 µg/ml low; 5.0 µg/ml high), or CHX (100µg/ml) + leptomycin 
B (2 ng/ml) and processed for immunocytochemistry using a HA (clone 3F10, Roche) 
monoclonal antibody and co-staining with Hoechst 33342 (5 µg/ml). 
 
RNA-IP 
These experiments were carried out essentially as described (Lin et al., 2005).  
HeLa cells (1x108) were suspended in 40 ml 1x PBS with 4 ml cross-linking buffer (100 
mM NaCl, 50 mM HEPES, 1 mM EDTA, 0.5 mM EGTA, 11% formaldehyde) for 30 min 
at RT with rocking.  The reaction was quenched with 2.2 ml 2.5 M glycine (pH 7.0) for 5 
min at RT then washed with 1X PBS and pelleted.  Cells were lysed by suspending in FA 
buffer (50 mM HEPES-KOH [pH 7.5], 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 
0.1% sodium deoxycholate, protease inhibitors) + RNase inhibitor (50 U/500 ml) and 
sonicated on a Branson sonifier at 25% power for 20 pulses of 20 sec with 30 rest on ice 
between each pulse.  The solution was made up to 25 mM MgCl2 and 5 mM CaCl2 then 
RNase-free DNase I (100 U/500ml) and RNase inhibitor (3 ml/500 ml) were added and 
incubated at 37°C for 30 min.  The reactions were centrifuged at 20,000 g for 15 min at 
4°C, keeping the supernatant for IPs.   
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For each RNA-IP reaction, 100 µl cleared extract was diluted with 900 ml ChIP 
buffer (50 mM HEPES pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, and 0.5% 
NP-40) to which 6 ml antibody (HS1-FRG1 or aPAT-9) and 4 ml RNase inhibitor were 
added then rotated for 12 hrs at 4°C.  Protein A Dynabeads (40 ml/IP) were washed twice 
in ChIP buffer then added to the IP reactions for 1 hr.  Dynabead IPs were washed 3X in 1 
ml wash buffer (50 mM Tris pH 7.4, 500 mM NaCl, 1% Triton X-100, 0.1% SDS) and 
RNA was eluted in 200 ml Elution Buffer (200 mM NaCl, 50 mM Tris pH 7.4, 20 mg 
Proteinase K) for 1 hr at 42°C.  Cross-linking was reversed by heating at 65°C for 5 hrs, 
and the RNA was extracted with acid equilibrated (pH 4.8) phenol:chloroform (5:1), 
ethanol precipitated, and brought up in DEPC-dH2O for use in RT-PCR (primers: #7, 
FXR-F and #8, FXR-R, Table 3.1). 
 
RNA electrophoretic mobility shift assay (REMSA)  
To generate full-length and deletion-containing FRG1 recombinant proteins, the 
pET23 plasmid constructs described above were transformed into E. coli BL21(DE3) cells 
and induced with 1 mM IPTG. The protein was purified using TALON resin (Clontech, 
Mountain View, CA) as per the manufacturer’s instructions.  The T7TS plasmid, 
containing the 5’ and 3’ untranslated regions (UTRs) of the Xenopus β-globin mRNA, was 
used as template for making mRNA probes. T7TS was linearized with Bgl II (New 
England Biolabs, NEB, Ipswich, MA) and in vitro transcribed using T7 RNA polymerase 
(NEB) and [32P]-UTP according to the manufacturer’s instructions, treated with TURBO 
DNase (Ambion, Inc., Austin, TX) for 15 min at 37˚C, purified on a 5% TBE gel and the 
extracted radiolabeled RNA was quantified by scintillation counter (Beckman LS6500).  
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The RNA-protein binding assay was performed in REMSA buffer (1 mM MgCl2, 10 mM 
Tris 7.4, 5% glycerol, 0.1% IGEPAL/NP-40, 50 mM NaCl, and 20 u RNasin (Promega, 
Madison, WI) with 50,000 CPM [32P] labeled probe.  Recombinant full-length FRG1 and 
deletion constructs were used at 150, 300, and 450 ng.  Reactions were incubated on ice 
for 20 min, analyzed by 5% TBE gel, and visualized by autoradiography. Unlabeled RNA 
probe, tRNA (Sigma-Aldrich), and T7TS plasmid, added to the reactions prior to the 
specific radiolabeled probe, were used as competitors. 
 
GST pull-down 
To test the FRG1-TAP interaction, recombinant GST and GST-Tap proteins were 
purified and bound to glutathione beads as described (Matzat et al., 2008).  Meanwhile, 
pET23-FRG1 constructs were used for in vitro transcription/translation (TnT) according 
to the manufacturer’s instructions (TnT-kit, Promega).  After washing the glutathione 
beads bound to GST proteins, the 35S methionine labeled proteins were added and 
subsequently incubated with the GST or GST-TAP beads with rotation for 3 hrs at 4°C.  
The FRG1-TAP interactions were carried out in 150 mM NaCl as described (Matzat et al., 
2008).  The beads were washed and proteins eluted by boiling with 20 µl of 2x SDS-
sample buffer, after which the whole samples were loaded onto a SDS-page gel. The gels 
were dried and exposed to film overnight. 
 
Microscopy 
Standard fluorescence microscopy was carried out using a HCL FL Fluotar 100X 
oil objective (NA=1.30) on an upright Leica DMR microscope. Images were captured 
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using a monochrome Retiga EXI Charge-Coupled Device (CCD) camera (Qimaging) 
driven by the In vivo software (version 3.2.0, Media Cybernetics). All images were 
processed using Adobe Photoshop to adjust brightness, contrast, size, and merged or split 
channels. Applied Precision Personal Deltavision was used for deconvolution images. 
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FIGURES AND 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Figure 3.1: Endogenous human FRG1 is both nuclear and cytoplasmic in HeLa cells, 
and nuclear FRG1 localizes predominantly to the nucleoli but not nuclear speckles. 
(A-C) Immunostaining using the HS1 FRG1 antibody (green) shows the endogenous 
FRG1 is both nuclear and cytoplasmic. Nuclear FRG1 is prominent in the DAPI-poor 
nucleoli (arrows). (D-G) Co-immunostaining for FRG1 (green) and the nucleolar marker 
fibrillarin (red) confirms the nucleolar localization of FRG1. (H-K) HeLa cells treated 
with ActD show FRG1 localizes to the granular component (GC) of the nucleoli (arrow) 
and not the fibrillarin stained dense fibrillar component (DFC) (arrowhead). (L-O) HeLa 
cells co-immunostained with FRG1 (green) does not co-localize with nuclear speckles 
indicated by SC35 staining (red).  Bars = 10 µm. 
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Figure 3.2: Endogenous FRG1 associates with nucleoli, Cajal bodies, and nascent 
RNA transcripts on lampbrush chromosome spreads in Xenopus laevis oocytes.  X. 
laevis oocyte nuclei isolated under oil and immunostained using antibodies specific for X. 
laevis FRG1 show FRG1 (green) localizes to (A-D) the nucleoli (arrow), Cajal bodies 
(arrowhead) with associating B snurposomes (indicated by *), and (E-L) nascent mRNAs 
that are being actively transcribed (blue arrowhead). DAPI staining (red) labels the DNA, 
marking the chromosome axis (blue arrow in F) and distinguishing nucleoli from Cajal 
bodies (B). (I-L) Focus on FRG1 localizing to the transcriptionally active chromosome 
loops, indicated by the blue arrowhead in L. The boxed area in K is shown magnified 3X 
in L. Bars = 10 µm. 
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Figure 3.3: Endogenous human FRG1 is associated with mRNA in vivo.  RNA-IPs 
using the HS1 FRG1 antibody show FRG1 associates with FXR1 mRNA transcripts in 
vivo in HeLa cells as assayed by RT-PCR. The FRG1 antibody specifically IP’ed FXR1 
mRNA (lanes 2 and 6) while a control non-specific (αPAT-9) antibody (lanes 3) did not.  
The unbound fraction confirms the presence of FRX1 mRNA in the control reaction (lane 
5).  The RT-PCRs are sensitive to RNase treatment (lanes 7 and 9), confirming that RNA 
is the IP’ed nucleic acid. 
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Figure 3.4: Human FRG1 interacts with RNA directly through its N-terminal NLS. 
(A) The schematic diagram showing protein domains of full-length human FRG1 and the 
deletion constructs. (B) The recombinant proteins of full-length human FRG1 and 
deletions shown by Coomassie blue staining of SDS-PAGE gel. (C) RNA gel shift 
experiment using radiolabeled, in vitro transcribed mRNA as probe (arrow) showed FRG1 
forms Protein-RNA complexes (arrowhead) through its N-terminal NLS as deleting this 
region abolished FRG1-RNA interaction. (D) The FRG1-RNA interaction is specific as 
both unlabeled probe and tRNA compete with radiolabeled probe while dsDNA does not. 
Box in A shows the region responsible for FRG1-RNA interaction. 
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Figure 3.5: FRG1 nuclear-cytoplasmic shuttling is independent of LMB but affected 
by inhibition of RNA polymerase II-mediated transcription.  HeLa cells, distinguished 
by clear DNA-poor regions (blue arrow), expressing HA-FRG1 were fused to murine 
C2C12 cells distinguished by DNA-rich foci (white arrow) in the presence of the 
translation inhibitor CHX for 3 hours with or without additional treatments described. 
Unfused C2C12 cells (examples indicated by *) do not express HA-FRG1.  (A-D) HA-
FRG1 expressed in HeLa cells localizes to C2C12 nuclei 3 hours after inducing fusion, 
showing that FRG1 shuttles between the nucleus and the cytoplasm.  Additional cell 
fusion experiments were carried out in the presence of LMB (E-H), low levels of AMD (I-
L) to shut down RNA polymerase I mediated transcription, and high levels (M-P) of AMD 
to shut down RNA polymerase I and II mediated transcription, respectively.  LMB or low 
does of AMD treatment do not affect FRG1 shuttling.  Under high AMD concentration, 
HA-FRG1 accumulated in the recipient C2C12 cells, and was excluded from the HeLa 
nucleoli. Bars = 10 µm. 
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Figure 3.6: FRG1 directly associates with TAP through the N-terminal NLS. (A) 
Radio-labeled, in vitro transcribed and translated FRG1 and deletion constructs of FRG1 
were incubated with GST-TAP or GST alone. Bound proteins were resolved by SDS-
PAGE followed by autoradiography. (B) The FRG1-TAP interaction is independent of 
nucleic acids as the interaction is insensitive to benzonase nuclease treatment. 
  76 
Table 3.1 PCR primers 
Primers used for making RBD deletions and RT-PCR 
#1: CCAACATATGGCCGAGTACTCCTACGTGAAGTC 
#2: CCAACTCGAGCTTGCAGTATCTGTCGGCTTTC 
#3: CATATGAGAGAAGAAGATGAAGAAACCCAGCTTG 
#4: CATATGAGTAAGAAGAAAAAGAGCAAAGATAAGAAA 
#5: CTCGAGAGCCTTTTTAAGAATTTTACTGTCTTC 
#6: CTCGAGGGATCTAATCTTGATCATTTCTTCTTC #7: CACAGTGGATGTTCCTGAGGATTTGAG 
#8: CATTTCTGGACATAAGCATCAACTTCGTAC 
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CHAPTER 4* 
 
FRG1 IS AN ACTIN­BUNDLING PROTEIN 
* Some of the data and writing is adapted from 
 
 Chia-Yun Jessica Sun, Silvana van Koningsbruggen, Kirsten Straasheijm, Rinse Klooster, Steven 
W. Long, Takako I. Jones, Michel Bellini, Lyne Levesque, William M. Brieher, Silvère M. van der Maarel, 
and Peter L. Jones. FSHD region gene 1 (FRG1) is a dynamic RNA-associated, actin bundling protein. 
Submitted for publication.  
INTRODUCTION 
FRG1 is one of the leading candidate genes for FSHD.  However, its relevance to 
FSHD pathology is unclear due to the lack of understanding of its molecular functions and 
inconsistent reports of mis-regulations in FSHD patient samples compared to controls 
(Arashiro et al., 2009; Gabellini et al., 2002; Jiang et al., 2003; Klooster et al., 2009; 
Masny et al., 2010; Osborne et al., 2007; Winokur et al., 2003).  In previous chapters, we 
have shown that FRG1 is a dynamic nuclear, cytoplasmic, and sarcomeric protein with 
distinct subcellular localizations.  In regards to RNA-biogenesis, we found that 
endogenous FRG1 localized to the nucleoli and Cajal bodies, sites where RNA-biogenesis 
takes place.  Further, FRG1 associates with RNA in vivo and binds directly to mRNA 
transcripts in vitro.  Using immunostaining, we also identified for the first time, the 
cytoplasmic pool of human and mouse endogenous FRG1 in multiple cell types.  This 
chapter will focus on the cytoplasmic functions of FRG1. 
In silico analysis of FRG1 revealed two N-terminal NLSs, a carboxyl bipartite 
NLS sequence, and a central fascin-like domain, found in the fascin family of actin-
bundling and cross-linking proteins (Kureishy et al., 2002).  Our lab has recently 
characterized the C. elegans FRG1 homolog, FRG-1, and, in addition to the conserved 
strong nucleolar localization, we found a cytoplasmic pool of FRG-1 localized to body-
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wall muscle dense bodies, structures functionally analogous to vertebrate Z-discs and 
costameres (Liu et al., 2010).  This striking Z-disc localization for FRG1 is conserved in 
mouse and human skeletal muscle (M. L. Hanel, submitted for publication).  Functionally, 
we found FRG-1 is an actin-binding and bundling protein in vitro suggesting FRG-1 may 
be a part of or involved in stabilization of the actin cytoskeleton (Liu et al., 2010).  The 
actin-binding and bundling activity is also conserved in human FRG1 (Liu et al., 2010).  
These data suggest a role for vertebrate FRG1 in muscle development and function, 
possibly through the regulation of the actin cytoskeleton, and make FRG1 an intriguing 
candidate gene for FSHD. 
In this chapter, we further investigated FRG1’s function in the cytoplasm and its 
association with the cytoskeleton.  We characterized human FRG1 actin binding activity 
and showed that FRG1 cytoplasmic localization is dependent upon the integrity of the 
actin cytoskeleton. 
 
RESULTS 
Human FRG1 binds F-actin and forms multimers in vitro 
Recently, we have shown that the C. elegans and human FRG1 bind to and bundle 
F-actin (Liu et al., 2010).  In order to further analyze the actin binding activity of human 
FRG1, a high-speed cosedimentation assay using recombinant human FRG1 was 
performed (Figure 4.1). Increasing concentrations of FRG1 were incubated with a 
consistent amount of F-actin and subjected to high-speed centrifugation to pellet the actin-
associated FRG1.  The ratios of FRG1 in the pellets (bound to actin) and supernatants (not 
bound to actin) were determined by SDS-PAGE and Coomassie BBR staining followed 
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by analysis with QuantityOne software.  The results showed that human FRG1 binds actin 
with a Kd = 0.16 ± 0.03 µM and Bmax = 1.54 ± 0.02 (corresponding to two FRG1 per 
actin monomer) (Figure 4.1A).  To determine if FRG1 could form the multimers required 
for F-actin cross-linking, a glutaraldehyde cross-linking assay using recombinant FRG1 
was performed.  A cross-linking time-course assay showed that FRG1 forms dimers and 
tetramers in vitro (Figure 4.1B), providing the multiple actin binding sites required for F-
actin cross-linking. 
 
Endogenous FRG1 interacts with actin cytoskeleton in C2C12 cells 
Since FRG1 is an actin binding protein, potentially FRG1 associates with the actin 
cytoskeleton in vivo.  Murine C2C12 cells subjected to immunostaining for FRG1 shows 
granular cytoplasmic staining (Figure 4.2A-D, Q-S).  To determine if cytoplasmic FRG1 
potentially associates with the actin cytoskeleton, as visualized by phalloidin staining, we 
treated the cells with various concentration of Latrunculin B (LatB) for 5 or 15 minutes. 
LatB inhibits actin polymerization and therefore disrupts actin cytoskeleton as indicated 
by loss of phalloidin staining (Figure 4.2A, E, I, M).  The intensity of the cytoplamic pool 
of FRG1 decreased gradually as the intensity of LatB treatment increased, and FRG1 
staining was abolished in phalloidin weak areas (Figure 4.2E-P) indicating that FRG1’s 
localization in the cytoplasm is dependent on the intact actin cytoskeleton in vivo. 
 
DISCUSSION 
The nuclear localization of FRG1 seems to be essential considering its double NLS 
and bipartite sequences; yet despite these signals, a consistent cytoplasmic pool of FRG1 
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remains.  This suggests that FRG1 is actively being retained in the cytoplasm and that the 
nuclear function of FRG1 is only part of the story.  We have previously proposed that 
FRG1 has a role beyond the nucleus as well.  The C. elegans FRG-1 bundles F-actin in 
vitro and localizes to the body wall muscle dense body, a structure analogous to the 
vertebrate muscle Z-disc and costameres (Liu et al., 2010).  Here we show that human 
FRG1 retains the conserved actin binding activity, binding to actin in a ratio of 2:1, 
similar to its C. elegans homolog, and forms dimers capable of bundling F-actin (Liu et 
al., 2010).  Thus, FRG1 may have a structural role in stabilizing the actin cytoskeleton or 
may be mediating other cellular functions by associating with the actin cytoskeleton.  In 
support of the latter situation, we showed that FRG1 requires the intact actin cytoskeleton 
for maintaining its particular punctate cytoplasmic localization suggesting that actin 
filaments actively anchor FRG1 in the cytoplasm.  Together with our findings in Chapter 
3 that FRG1 is involved in RNA-biogenesis and may be mediating mRNA export through 
the TAP/NXT1 pathway; we propose that the nuclear and cytoplasmic functions are 
linked through RNA.  FRG1 may be involved in mRNA export and anchor mRNA at its 
designated location through associating with actin cytoskeleton for localized translation.  
This could also be related to the skeletal muscle Z-disc localization of FRG1 in mouse and 
human, as FRG1 anchors the mRNA transcripts at the Z-disc for localized translation.  
Interestingly, several Z-disc proteins have been shown to co-localize with their cognate 
mRNAs in cultured skeletal muscle (Morris and Fulton, 1994).  Another important aspect 
of Z-disc localization of FRG1 is that disruptions of numerous Z-disc proteins are causally 
related to myriad myopathies (McNally and Pytel, 2007; Selcen and Carpen, 2008).  Z-
disc is the essential sarcomeric structure to ensure proper aliments of the sarcomeres, 
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therefore maintains muscle integrity during contraction.  The actin binding and bundling 
activities of FRG1 could also be important as it could be part of the structural proteins at 
the Z-disc. 
Our data suggest FRG1 is a multifunctional protein with distinct subcellular 
localizations and the subcellular distribution of FRG1 may be highly regulated.  Even 
small alterations of FRG1 protein levels could change the subcellular distribution of 
FRG1, potentially dysregulating its function, and ultimately leads to disruption of muscle 
development or integrity. 
 
MATERIALS AND METHODS 
Cell culture 
C2C12 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 2 mM L-glutamine, supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin–streptomycin (pen/strep). Cells were incubated with 5% CO2 at 37°C.  For 
Latrunculin B (LatB) treatments, C2C12 cells were treated with indicated concentrations 
of LatB (Invitrogen Corp., Carlsbad, CA) for 5 or 15 min as indicated.  After Lat B 
treatment, cells were fixed with 2% FA for 15 min at RT and subjected to immunostaining 
described below. 
 
Immunocytochemistry 
C2C12 cells were fixed in 2% formaldehyde (FA) in PBS for 15 min at room 
temperature (RT). After fixation, cells were made permeable with 0.25% Triton-X 100 in 
PBS for 10 min on ice, and subsequently blocked with 2% BSA in PBS for 30 min at RT. 
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Primary antibody incubation was carried out overnight at 4°C in PBS with 2% BSA, and 
secondary antibody incubation was for 40 min at RT in PBS.  Secondary antibodies used 
were pre-cleared FITC-conjugated donkey anti-rabbit (Jackson ImmunoResearch 
Laboratories Inc) used at 1:100.  F-actin was visualized with 5 U/ml rhodamine-phalloidin 
(Invitrogen Corp) incubated for 30 min at RT.  The 4,6-diamidino-2-phenylindole (DAPI) 
was used at 1µg/ml.  
 
Actin binding assay 
Actin was purified from rabbit skeletal muscle as described (Pardee and Spudich, 
1982).  Recombinant full-length FRG1 generated as described in Chapter 3 was further 
purified by ion exchange chromatography, binding to MonoS resin using an AKTA-FPLC 
(GE Healthcare), step eluted between 350 and 700 mM NaCl in 10 mM HEPES pH 7.5 
and 10% glycerol, and dialyzed to 50 mM NaCl.  Actin co-sedimentation assays were 
carried out as described with minor modifications (Ono et al., 1997). For high-speed 
sedimentation assays, increasing amounts of recombinant FRG1 (7-30 mM as monomer) 
were incubated with G-actin (final concentration 6 µM) in 50 mM NaCl in a total volume 
of 50 µl at RT for 2 hrs and then centrifuged at 100,000 g for 20 min at RT. The amounts 
of FRG1 and F-actin in the supernatants and pellets were determined by densitometry 
using Coomassie-Blue-stained 10% SDS-PAGE.  The intensities of the stained 
polypeptide bands were quantified by volume integration after local background 
subtraction using Bio-Rad Quantity One software (Bio-Rad Laboratories, Hercules, CA).  
Subtracting the percentage of FRG1 in the pellet without actin was used to normalize the 
FRG1. The binding data from four independent experiments were analyzed by fitting to 
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the Michaelis-Menton equation, Y=Bmax*X/(Kd+X), using the nonlinear regression 
function of Prism 5 (GraphPad Software), where Y is FRG1 per F-actin (mol/mol) in the 
pellet and X is the FRG1 concentration (micromolar) remaining in the supernatant. 
 
Glutaraldehyde cross-linking 
Recombinant full-length FRG1 protein (0.1 mg/ml) was incubated with 0.01% 
glutaraldehyde in 1X PBS in 1 ml at RT. Samples (50 µl) were removed at the indicated 
time intervals and the reactions were stopped by the addition of 2X Laemmli SDS-PAGE 
buffer, boiled, and separated by SDS-PAGE (12%).  Protein was detected by western 
blotting using the HS2 antibody described above. 
 
Microscopy 
Standard fluorescence microscopy was carried out using a HCL FL Fluotar 100X 
oil objective (NA=1.30) on an upright Leica DMR microscope. Images were captured 
using a monochrome Retiga EXI Charge-Coupled Device (CCD) camera (Qimaging) 
driven by the In vivo software (version 3.2.0, Media Cybernetics). All images were 
processed using Adobe Photoshop to adjust brightness, contrast, size, and merged or split 
channels. Applied Precision Personal Deltavision was used for deconvolution images. 
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FIGURES 
 
Figure 4.1: Human FRG1 binds F-actin and forms multimers in vitro. (A) High speed 
cosedimentation assay using an increasing amount of recombinant human FRG1 with a 
constant concentration of F-actin shows saturation. (B) Western blot analysis of a 
glutaraldehyde crosslinking time-course assay using recombinant human FRG1 shows 
FRG1 can readily form dimers and tetramers in vitro. 
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Figure 4.2: Endogenous FRG1 requires the actin cytoskeleton for cytoplasmic 
localization in murine C2C12 cells. (A-D, Q-S) Cytoplasmic pool of FRG1 appeared 
granular and associated with actin filaments labeled by rhodamine-phalloidin staining 
(arrowheads in S). Boxed area in D is shown magnified 2X in Q-S. (E-P) Cells were 
treated with variable concentrations of Latrunculin B (LatB) for 5 or 15 minutes as 
indicated. FRG1 staining decreased or was abolished (arrows) in areas of LatB disrupted 
actin filaments as indicated by weak phalloidin staining. 
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CHAPTER 5 
TRANSLATIONAL IMPACT TOWARD FSHD 
 
This thesis aims to understand the normal cellular function of the human FRG1 
protein, considered one of the leading candidates for mediating FSHD pathophysiology.  
Even though the genetic lesion of FSHD was mapped twenty years ago to the D4Z4 repeat 
array on chromosome 4q35, the subtelemeric region of chromosome 4q (Wijmenga et al., 
1990; Wijmenga et al., 1992), the molecular mechanism of the disease remains elusive as 
how the contraction of the array leads to FSHD pathology.  It is unclear whether the repeat 
element itself contains the gene responsible for disease pathogenesis (DUX4), or the 
contraction causes a downstream effect on other candidate genes in a trans or cis fashion, 
or the disease is a combination of both mechanisms.  Expression profile studies and 
analyses failed to show consistent mis-regulation of any candidate gene in patient samples 
compared to normal individuals (Dixit et al., 2007; Gabellini et al., 2002; Jiang et al., 
2003; Klooster et al., 2009; Masny et al., 2010; Osborne et al., 2007; Winokur et al., 
2003).  This can partially be explained by the differences in the samples collected, 
processing procedures, or the techniques used for analysis.  Muscle biopsy that 
appropriately represents the disease progression is hard to collect as the affected muscles 
often show fibrotic or adipose infiltration, and biopsies collected are usually mixed with 
multiple cell types such as epithelial cells.  Thus, in order to understand the molecular 
mechanism of FSHD pathogenesis, it is important to investigate the normal cellular 
functions of the candidate genes and see how its mis-regulation would contribute to FSHD 
pathology.  Our work here provides insights into the subcellular localizations and 
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biological activities of FRG1, and shows how mis-regulation of FRG1 can potentially be 
detrimental to muscle development or integrity.  Further, these activities would have 
additional interesting implications beyond their significance in muscle development 
should FRG1 be determined to be involved in mediating FSHD pathophysiology. 
We have previously shown that FRG1 is critical for vertebrate musculature and 
vasculature development; here we have addressed the potential for FRG1 misexpression to 
lead to a muscular dystrophy phenotype by understanding its normal cellular function.  
We have further investigated the subcellular localizations of endogenous FRG1 and 
discovered both nuclear and cytoplasmic pools of FRG1 in multiple cell types.  The 
distribution of FRG1 is consistent between most cell types with very prominent nuclear 
staining (granular staining in the nucleoplasm and enriched in nucleoli) followed by 
granular staining in the cytoplasm, except for undifferentiated and fully differentiated 
HSMM (human skeletal muscle myoblasts) showing the greatest amount in the cytoplasm.  
The subcellular localization greatly changes during myogenesis with increased nuclear 
and nucleolar staining in early myogenesis, and eventually localized to the Z-disc in 
mature myotubes.  This is consistent with previous finding that FRG1 level is upregulated 
during myogenic differentiation in human myoblasts (Bodega et al., 2007) (T.I. Jones, 
unpublished observation), and the overexpressed FRG1 is predominantly nuclear and 
nucleolar (van Koningsbruggen et al., 2004).  The Z-disc localization in mature HSMM 
myotubes is in agreement with our finding in C. elegans that FRG-1 (FRG1 ortholog) 
localizes to the body wall dense bodies, which is functionally analogous to the vertebrate 
Z-discs and costameres (Moerman and Williams, 2006).  This is the first link between a 
FSHD candidate gene and the sarcomeric phenotype of FSHD, where the structures at the 
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sarcolemma are misaligned and the attachment between the sarcolemma and the 
underlying contractile are disrupted in FSHD patient samples (Reed et al., 2006).  
Therefore, FRG1 is similarly localized with many other proteins associated with 
myopathies, strongly implicating its involvement in FSHD. 
Focusing on the nuclear function of FRG1, here we show endogenous FRG1 
localizes to Cajal bodies (CBs) and the granular component (GC) of nucleoli, as well as 
associated with nascent mRNA transcripts and the actively transcribed regions of the 
euchromatin.  CBs are nuclear bodies that store factors involved in transcription and RNA 
processing, and sites for snRNP biogenesis (Austin and Bellini, 2010; Gall, 2003).  
Nucleoli are sites for transcription assembly of pre-ribosomal particles, maturations of 
some RNP particles, and assembly of the RNA splicing machinery (Austin and Bellini, 
2010; Boisvert et al., 2007).  Lampbrush chromosome spreads from X. laevis oocytes 
confirmed localization of endogenous FRG1 in CBs and nucleoli, and further indicate 
FRG1 associate with nascent RNA polymerase II generated mRNAs in vivo.  RNA-IP 
from HeLa cells also showed FRG1 associates with mRNA transcripts in vivo, and the 
association may be direct as FRG1 bind mRNA transcripts in vitro through its N-terminal 
NLS.  Together, these data further indicates FRG1 is involved in RNA-biogenesis or pre-
mRNA processing.  Thus, FRG1 is a nuclear and cytoplasmic protein associated with the 
contractile machinery and RNA transcripts. 
Our collaborative work with Silvére van der Maarel’s group in Leiden, the 
Netherlands, has led to the identification of two FRG1 protein binding partners, 
karyopherinα2 and TAP.  Karyopherinα2, a nuclear import protein, is a prominent FRG1 
binding partner by yeast-two-hybrid screens.  A direct interaction was confirmed by GST 
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pull-down and co-IP experiments (Sun et al., submitted for publication).  Although 
proteins such as FRG1 (30 kb) are small enough to pass through the nuclear pore by 
diffusion, active nuclear transport via the nuclear import receptor karyopherinα2 results in 
rapid and efficient nuclear accumulation, which likely indicates an essential nuclear 
function for FRG1.  The N-terminal NLS region (contains two NLS sequences, NLS1 and 
NLS2), not the carboxyl bipartite NLS, was demonstrated to be the functional NLS for 
FRG1 (van Koningsbruggen et al., 2004).  We further mapped NLS2 as the essential NLS 
and showed that the subcellular localization of FRG1 can potentially be regulated through 
phosphorylation to ensure a spatial-temporal specific distribution of FRG1 (Sun et al., 
submitted for publication).  TAP, an mRNA export receptor, is a new binding partner of 
FRG1, suggesting FRG1 may involve in mediating mRNA export through TAP/NXT1 
pathway.  Interestingly, FRG1 interacts directly with TAP through the N-terminal NLS, 
the functional NLS for FRG1 and the potential RNA binding domain.  FRG1 may interact 
with TAP/NXT1 heterodimer and mediate mRNA export, and continue to associate with 
mRNA transcripts in the cytoplasm, therefore masking the NLS and maintain its 
cytoplasmic localization.  Thus, FRG1 is a sarcomeric protein potentially involved in 
mRNA trafficking. 
Further, we investigated the cytoplasmic function of and showed that human 
FRG1 bundles actin in vitro and may potentially be regulated through phosphorylation of 
two potential phosphorylation sites within the fascin like domain (Appendix A).  
Considering the associations of FRG1 with mRNA biogenesis and trafficking, we propose 
a model whereby FRG1’s nuclear and cytoplasmic functions are linked through RNA 
(Figure 5.1).  FRG1 may associate with mRNA transcripts in the nucleus, which are then 
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exported together to the cytoplasm, mediated through the TAP/NXT1 pathway, where the 
actin cytoskeleton anchors the FRG1-mRNA complex at its designated location.  This is 
in agreement with our finding that the nuclear export of FRG1 is dependent on RNA, as 
inhibiting RNA polymerase II results in the accumulation of FRG1 in the recipient nuclei; 
and intact actin cytoskeleton is required for the granular staining of FRG1 in the 
cytoplasm of murine C2C12 cells. 
Localized translation of mRNA has emerged as a new mechanism for regulating 
cellular protein synthesis in a spatial-temporal manner.  In this model, mRNA transcripts 
are associated with repressor complexes and are silenced during transport until they reach 
their final destination.  Translational repressors prevent protein synthesis by targeting 
different regulators of the translation process; the most frequently regulated step is 
translation initiation, the general rate-limiting step (Besse and Ephrussi, 2008).  
Translation of targeted mRNAs is activated upon the arrival at its subcellular destination, 
in response to spatial cues.  Or, the targeted mRNAs are stored in a dormant state at their 
designated location, and is only activated in response to specific external signals (Besse 
and Ephrussi, 2008).  Translational derepression might commonly be mediated by 
decreasing the affinity of translational repressors with the target mRNAs, and allow the 
initiation of translation to proceed. 
FRG1 may potentially be involved in this process as FRG1 is deposited on 
mRNAs in the nucleus, mediating its export through the TAP/NXT1 pathway, anchoring 
the targeted mRNAs at its final locations in a repressed state, waiting for activation signals 
in response to external stress.  We have found FRG1 localizes to Z-disc the in mature 
myotubes, and interestingly, several Z-disc proteins have been shown to co-localize with 
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their cognate mRNAs in cultured skeletal muscle (Morris and Fulton, 1994).  Further, 
various translational regulators that are found in transport-RNP complexes are shuttling 
proteins that contain nuclear localization signals and accumulate at least transiently in the 
nucleus (Besse and Ephrussi, 2008).  Finally, localizing mRNAs seem to co-sediment 
poorly with fractions containing actively translated mRNAs (polysomal fractions), which 
is consistent with our finding that FRG1 does not associate with actively translated 
polyribosomes (unpublished observation). 
FRG1 is clearly an important multifunctional protein involved in muscle 
development, however a role in FSHD pathophysiology is controversial due to the failure 
to consistently find any significant changes in FRG1 levels between patients and 
unaffected individuals.  Still, recent data towards understanding FRG1 is compelling. 
Overexpression of FRG1 specifically disrupts development of the vertebrate musculature 
and vasculature, the two tissues most affected in FSHD (Hanel et al., 2009; Wuebbles et 
al., 2009).  Cytoplasmic FRG1 localizes to the skeletal muscle Z-disc in mouse and 
humans, the subcellular localization of numerous proteins related to myriad myopathies 
(McNally and Pytel, 2007; Selcen and Carpen, 2008).  We subsequently added to the 
circumstantial evidence supporting FRG1’s potential in FSHD by showing FRG1 is a 
dynamic RNA-associated actin binding protein in consistent with previous finding that 
RNA biogenesis is disrupted in FSHD (Davidovic et al., 2008; Gabellini et al., 2006).  In 
addition, FRG1’s interactions with both a nuclear importer and a nuclear exporter indicate 
its subcellular localization is highly regulated.  Interestingly, in all systems tested 
including mammalian cell culture, C. elegans, Xenopus, and Drosophila, overexpressed 
FRG1 preferentially accumulates in the nucleus (Liu et al., 2010; van Koningsbruggen et 
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al., 2004; van Koningsbruggen et al., 2007) (PL Jones unpublished observation).  Even 
small alterations of FRG1 protein levels could change the subcellular distribution of 
FRG1, potentially dysregulating its function.  Increasing nuclear levels of FRG1 may 
ultimately result in mis-spliced mRNA transcripts, altered mRNA stability, or affect 
mRNA transport, any of which could adversely affect maintenance of muscle integrity. 
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FIGURES 
 
Figure 5.1: Proposed model illustrating FRG1 activities.  FRG1, translated in the 
cytoplasm, is transported to the nucleus via the nuclear importer receptor karyopherinα2 
in a phosphorylation-dependent manner. Once in the nucleus, FRG1 either translocates to 
the nucleolus or associates with nascent mRNA transcripts that are exported together 
through the TAP/NXT1 pathway. In the cytoplasm, the FRG1-mRNA complexes are 
transported through an unknown mechanism and anchored at its final location by the actin 
cytoskeleton. 
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APPENDIX A 
PHOSPHORYLATION OF HUMAN FRG1 AFFECTS ITS ACTIN BUNDLING ACTIVITY  
 
INTRODUCTION 
 FRG1 in one of the leading candidate genes for FSHD, however, its involvement 
in FSHD pathophysiology is unclear and its precise function unknown.  FRG1 has 
multiple NLS sequences and has a proposed role in RNA-biogenesis (van 
Koningsbruggen et al., 2004; van Koningsbruggen et al., 2007).  Further, we have shown 
that FRG1 potentially is involved in mRNA transport and regulation.  FRG1 contains a 
central fascin-like domain, which is found in actin bundling or cross-linking proteins 
(Kureishy et al., 2002) and we have shown that human FRG1 can bind actin (two FRG1s 
per actin monomer) and bundle F-actin in vitro and requires F-actin for its cytoplasmic 
localization in vivo.  Since FRG1 only has one fascin-like domain, and therefore likely 
only one actin-binding domain, FRG1 would require multimerization for cross-linking 
actin.  In fact, FRG1 can associate with actin through multimerization, as FRG1 forms 
homodimers and homotetramers in vitro as shown by a glutaraldehyde cross-linking 
assay.  Here, we further characterize FRG1’s actin binding and bundling. 
 The association of FRG1 with the actin cytoskeleton was discussed in Chapter 4; 
here we want to investigate how this association can be regulated.  We made a series of 
deletions and several point mutations within the fascin-like domain of FRG1, generated 
recombinant protein, and mapped the regions important for actin bundling activity using 
an in vitro fluorescent F-actin bundling assay.  Three separate regions within the FRG1 
fascin-like domain appeared to mediate the actin bundling activity.  Interestingly, two 
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potential highly conserved protein kinase C (PKC) phosphorylation sites were found in 
two of these regions and several actin bundling proteins, including fascin, are regulated by 
PKC phosphorylation in their actin binding sites.  We further showed that FRG1 can be 
phosphorylated in vitro, and mutation of the phosphorylation sites abolishes the actin 
bundling activity of FRG1.  These data suggest FRG1’s actin bundling activity is 
regulated by phosphorylation. 
 
RESULTS 
Three regions within FRG1’s fascin-like domain are required for F-actin bundling 
activity 
A series of internal FRG1 deletion constructs, each containing a deletion of 15-20 amino 
acids, spanning the fascin-like domain, were made in order to map the region of FRG1 
that mediates its F-actin bundling activity (Figure A.1).  A fluorescent F-actin bundling 
assay was carried out by incubating the recombinant FRG1 deletion protein of interest 
with TMR-labeled F-actin, which allows the bundled F-actin be readily visualized under a 
fluorescent microscope (Figure A.2).  Using this assay, three separate regions, Δ72-86, 
Δ103−118, and Δ134-177, were found to be required for the actin bundling activity of 
FRG1 (Figure A.3). 
 
FRG1 can be phosphorylated in vitro by PKC 
Interestingly, in silico sequence analysis of the predicted FRG1 amino acid 
sequence identified two potential PKC phosphorylation sites, FTL and KSG, within the 
fascin-like domain.  These sites are 100% evolutionarily conserved from human through 
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Drosophila and each resides in a distinct region that is required for the actin bundling 
activity (Figure A.4).  To determine whether these PKC sites are potential substrates for 
PKC we performed an in vitro phosphorylation assay using recombinant PKC and [32P] γ-
ATP on recombinant full-length FRG1 or FRG1 point mutation constructs where the FTL 
and/or KSG residues were changed to alanines (A).  We found that the full-length FRG1 
was phosphorylated by PKC and the phosphorylation level decreased significantly upon 
mutation of each of the potential PKC sites (Figure A.5).  Next, we want to see if the point 
mutations of the potential PKC sites would affect the actin bundling activity of FRG1.  
We performed the fluorescent actin bundling assay on the recombinant FRG1 with point 
mutations and showed mutation of the potential PKC sites abolishes the actin bundling 
activity of FRG1. Thus, FRG1’s actin bundling activity potentially could be regulated by 
PKC. 
 
DISCUSSION 
FRG1 is a leading candidate gene for FSHD; however, its involvement in FSHD 
pathophysiology is not yet established due to its unknown function and inconsistent 
reports of its misregulation in FSHD samples compared to controls (Gabellini et al., 2002; 
Jiang et al., 2003; Klooster et al., 2009; Masny et al., 2010; Osborne et al., 2007; Winokur 
et al., 2003).  The field has focused on its nuclear function based on the initial subcellular 
localization studies of exogenously expressed FRG1 showing FRG1 is exclusively nuclear 
in cells overexpressing epitope-tagged FRG1 (van Koningsbruggen et al., 2004).  We have 
shown that the endogenous FRG1 is abundant in the cytoplasm of all cells tested and the 
intact actin cytoskeleton is required for the granular cytoplasmic staining of FRG1 in 
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C2C12 cells (Chapter 4).  Interestingly, we have also shown that FRG1 has an actin 
binding and bundling activity that is conversed in its C. elegans homolog, FRG-1 (Liu et 
al., 2010), consistent with a cytoplasmic role.  This study focused on this actin bundling 
activity, mediated by FRG1’s fascin-like domain.  Fascins are a conserved group of actin-
bundling proteins that stabilize actin filaments for cellular processes.  Each vertebrate 
fascin contains four fascin-like domains, and two of which contain single actin-binding 
sites (Edwards and Bryan, 1995; Kureishy et al., 2002).  FRG1 contains a single fascin-
like domain, and we have previously shown that FRG1 forms homodimers in vitro, which 
provides the multiple actin-binding sites necessary for F-actin bundling.  Here we have 
mapped three regions within the fascin-like domain that mediates the actin bundling 
activity of FRG1.  These regions may be the dimerization or actin binding domains of 
FRG1, or regulate actin bundling activity through other mechanisms. 
Two highly conserved potential PKC sites reside in two of the three regions 
mediating FRG1 actin bundling activity.  We have shown both PKC sites are functional in 
vitro, and mutation of each PKC sites is sufficient to abolish the actin bundling activity of 
FRG1.  Interestingly, the actin binding and bundling activities of human Fascin are also 
regulated through phosphorylation (Ono et al., 1997; Yamakita et al., 1996).  Further 
experiments are required to investigate if FRG1 is phosphorylated in vivo, and how 
phosphorylation of FRG1 affects the actin binding activity. 
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MATERIALS AND METHODS 
DNA constructs 
All PCR primers are listed in Table A1.  To generate the FRG1 His-tagged 
bacterial expression constructs, the cDNA for the full-length human FRG1 coding 
sequence was PCR amplified (primers #1 and #2) and subcloned between the NdeI and 
XhoI restriction sites into pET-23b vector (Novagen, Gibbstown, NJ).  For the fascin 
deletion constructs, use Δ58-71 as example, two PCR reactions were generated using #1 
and #3, #2 and #4, respectively.  The PCR products were then used as templates for 
another PCR reaction using primer #1 and #2.  The final PCR product was subcloned 
between the NdeI and XhoI restriction sites into pET-23b vector (Novagen, Gibbstown, 
NJ).  For point mutations of potential phosphorylation sites, FTL and KSG, these sites 
were replaced by three alanines (A) using a similar technique as making the fasin domain 
deletions.  For FTL site, two separate PCR were performed using primer sets #1 and  #19, 
#2 and #20, respectively.  The PCR products were subsequently used as templates for 
PCR reaction using primers #1 and #2, and the final product was subcloned between the 
NdeI and XhoI restriction sites into pET-23b vector. For KSG site, two separate PCR 
were performed using primer sets #1 and  #21, #2 and #22, respectively.  The PCR 
products were subsequently used as templates for PCR reaction using primers #1 and #2, 
and the final product was subcloned between the NdeI and XhoI restriction sites into pET-
23b vector. 
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Fluorescent actin bundling assay 
Actin was purified from rabbit skeletal muscle as described (Pardee and Spudich, 
1982).  To generate full-length and deletion-containing FRG1 recombinant proteins, the 
pET23 plasmid constructs described above were transformed into E. coli BL21 (DE3) 
cells and induced with 1 mM IPTG. The protein was purified using TALON resin 
(Clontech, Mountain View, CA) as per the manufacturer’s instructions.  Recombinant 
full-length FRG1 or deletion construct proteins were further purified by ion exchange 
chromatography, binding to MonoS resin using an AKTA-FPLC (GE Healthcare), eluted 
with gradient salt between 100 and 1000 mM NaCl and peak fractions containing FRG1 
proteins are selected and used for the assay.  A mixture of unlabeled and 
tetramethylrhodamine labeled G-actin (TMR-G-actin) in a ratio of 1:1 is prepared in G-
buffer (2mM Tris pH 8.0, 0.2 mM ATP, 0.5 mM DTT, and 0.2 mM CaCl2).  Full-length 
and fascin domain deletions of FRG1 were incubated with G-actin and TMR-G-actin in 
bundling buffer (100 mM HEPES pH7.4, 50 mM KCl, 2 mM MgCl2, 2 mM ATP, and 1 
mM EGTA).  The reaction was carried out in RT for 5 minutes.  3 µl of reaction was 
visualized under fluorescent microscope to detect F-actin bundles. 
 
In vitro phosphorylation assay of FRG1 
Full-length and point mutations of FRG1 are expressed in E. coli BL21 (DE3) and 
purified by ion exchange chromatography (binding to MonoS resin) as described above.  
The phosphorylation assay was carried out essentially as described with minor 
modifications (Yamakita et al., 1996).  Full-length and point mutation constructs of FRG1 
were incubated with Protein Kinase C (PKC, Enzo) in a final concentration of 1 µg/ml, 
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and [γ-32 P] labeled ATP (PerkinElmer) in phosphorylation buffer (30 mM KCl, 3 mM 
MgCl2, 0.2 mM EGTA, and 20 mM Tris pH 7.5) in the presence of PMA (phorbal 12-
myristate 13 acetate, a potent PKC activator, Enzo) and DTT in the final concentration of 
100 ng/ml and 0.5 mM, respectively.  The reaction was incubated for 1 hour at 30°C.  1.2 
µg of full-length FRG1 or point mutation constructs were used in each reaction.  After 
incubation, the reactions were analyzed by Coomassie-Blue-stained 12% SDS-PAGE, and 
the phosphorylation levels were visualized by autoradiography.  
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FIGURES AND TABLES 
 
 
Figure A.1: Schematic view of FRG1 fascin domain deletions.  A series of deletion 
constructs, each deleting 15-20 amino acids spanning the fascin-like domain, were made 
to map regions that mediates the actin bundling activity of FRG1. 
 
 
 
Figure A.2: Fluorescent actin bundling assay. Full-length FRG1 or fascin domain 
deletions were incubated with TMR-labeled F-actin, and visualized under fluorescent 
microscope for bundled F-actin. 
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Figure A.3: Three separate regions within fascin-like domain are responsible for 
mediating actin bundling activity. Using deletion constructs in fluorescent bundling 
assay, we identified three regions responsible for actin bundling activity: Δ72-86, 
Δ103−118, and Δ134-177.  Mutation of potential PKC sites abolishes the actin bundling 
activity of FRG1.  Proteins used for fluorescent bundling assay are indicated and Bar = 10 
µm.
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Figure A.4: FRG1 contains two highly conserved PKC sites.  In silico sequence 
analysis revealed two potential phosphorylation sites (boxed region) in the fascin-like 
domain and they are highly conserved. 
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Figure A.5: Human FRG1 protein can be phosphorylated in vitro.  Full-length FRG1 
can be phosphorylated in vitro by Protein Kinase C (PKC).  Mutating either FTL or KSG 
site leads to decreased phosphorylation level.  Phosphorylation levels were visualized by 
autoradiography; proteins of input were visualized through Coomassie-Blue-staining of 
the same SDS-PAGE gel used for autoradiography.
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Table A.1 PCR primers 
Primers used for making fascin domain deletions and point mutations for human FRG1. 
 
#1: CCAACATATGGCCGAGTACTCCTACGTGAAGTC 
#2: CCAACTCGAGCTTGCAGTATCTGTCGGCTTTC 
#3 (Δ58-71): ACCATTGTCGAGTGCGGCGGCCGCTGAAATTTCACCAAA 
#4 (Δ58-71): TTTGGTGAAATTTCAGCGGCCGCCGCACTCGACAATGGT 
#5 (Δ72-86): AGGGCCCTCATCAACGGCGGCCGCATGTATATAGGTTCC 
#6 (Δ72-86): GGAACCTATATACATGCGGCCGCCGTTGATGAGGGCCCT 
#7 (Δ87-102): GATTCTGGAATCAGAGGCGGCCGCTTCTTTGTGTGGAGC 
#8 (Δ87-102): GCTCCACACAAAGAAGCGGCCGCCTCTGATTCCAGAATC 
#9 (Δ103-118): TCCATCTGAATTTATGGCGGCCGCTAATTTGACAGCCGT 
#10 (Δ103-118): ACGGCTGTCAAATTAGCGGCCGCCATAAATTCAGATGGA 
#11 (Δ119-133): CCATTGTTCTCTTGGGGCGGCCGCACCAAGATATTTTCC 
#12 (Δ119-133): GGAAAATATCTTGGTGCGGCCGCCCCAAGAGAACAATGG 
#13 (Δ134-148): ATTTGAGGCCAACAAGGCGGCCGCTCCAATTGCATCTGA 
#14 (Δ134-148): TCAGATGCAATTGGAGCGGCCGCCTTGTTGGCCTCAAAT 
#15 (Δ149-162): TGCTTCTATGTCCCCGGCGGCCGCAGCCATTTTCCCATT 
#16 (Δ149-162): AATGGGAAAATGGCTGCGGCCGCCGGGGACATAGAAGCA 
#17 (Δ163-177): GGATCTAATCTTGATGGCGGCCGCTGCTTCATTGCATCT 
#18 (Δ163-177): AGATGCAATGAAGCAGCGGCCGCCATCAAGATTAGATCC 
#19 (FTL): TTTGTGTGGAGCTCCGGCGGCCGCAAGACCATTGTCGAG 
#20 (FTL): CTCGACAATGGTCTTGCGGCCGCCGGAGCTCCACACAAA 
#21 (KSG): AAGATATTTTCCATAGGCGGCCGCCAGGGCGATTCTGGA 
#22 (KSG): TCCAGAATCGCCCTGGCGGCCGCCTATGGAAAATATCTT 
 
 
 
 
 
 
 
